Insights into the role of renin-angiotensin systems in regulating mitochondrial function by Astin, RJ
1 
 
 
 
 
Insights into the role of 
renin-angiotensin systems 
in regulating mitochondrial 
function 
 
 
 
Dr Rónan Astin 
UCL 
 
PhD 
  
2 
 
 
 
 
 
 
I, Rónan Astin, confirm that the work presented in this thesis is my own. Where 
data has been gathered in collaboration with others, this is clearly indicated in 
the thesis. Where information has been derived from other sources I confirm that 
this has also been clearly indicated here within. 
 
 
Signed: 
  
3 
 
Acknowledgements 
In completing this work I owe a debt of gratitude to many people. Chief among them are 
my supervisors, Professor Hugh Montgomery and Dr Gyorgy Szabadkai. My post-
doctoral colleagues in the Starling Laboratory (UCL), Dr Jose Vicencio, Dr Zhi Yao and 
Dr Will Kotiadis, offered invaluable advice and insight. I also thank the members of the 
Institute for Human Health and Performance (with special mention to Drs. Zudin 
Puthucheary, Julie Sanders and Vishal Nangalia) along with Dr Maciej Garbowski (UCL 
Department of Haematology) and Miss Sahar Freemantle (UCL Department of Cell and 
Developmental Biology) for their camaraderie and support throughout.  
  
4 
 
Abstract 
 
The renin-angiotensin system (RAS) is an evolutionarily conserved enzyme system 
which plays a major role in circulatory homeostasis. This traditional concept of the RAS 
as a circulating enzyme system has, over the last two decades, been challenged. It is 
now well established that RAS exist within most tissues and operate independently of 
the circulating system, with the complexity of the RAS increasing as novel effector 
proteins, enzymes and receptors have been identified. It is now accepted that RAS can 
act intracellularly, and in some organs entire RAS exist within single cells. The 
functions of these RAS are still being elucidated, but data suggest a role in regulating 
metabolic efficiency.  
Mitochondria are intracellular organelles responsible for producing the main energy 
currency of the cell – adenosine triphosphate (ATP). Understanding of their functions 
has expanded to include cell signalling, regulating cell cycle, and modulating metabolic 
function. Over the last few years, the idea that RAS may influence mitochondrial 
function has gained credence. Mitochondrial number, replication and function all appear 
to be affected by RAS activity, whilst components of the RAS have been identified in 
association with mitochondria raising the possibility of a mitochondrial RAS. Thus, I 
examined the hypothesis that a RAS exists within mitochondria. 
This hypothesis was tested using four complimentary techniques. Existence of RAS 
proteins within the mitochondrial proteome was sought by interrogation of established 
databases and mass spectrometric analyses of mitochondria isolated from rat liver; no 
major RAS proteins were found. Attempts to identify a RAS receptor by 
immunochemistry failed, whilst radioligand binding studies revealed a binding site in 
membranes associated with mitochondria (MAM) but not mitochondria themselves. 
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Finally, no effect of AngII on mitochondrial respiration could be found at physiological or 
supra-physiological concentrations.  
In conclusion, I could find no evidence of a mitochondrial RAS in rat liver suggesting 
the effects of the RAS on cellular metabolism are not mediated by direct interaction with 
mitochondria.  
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1. INTRODUCTION 
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1.1. The endocrine RAS 
The circulating (endocrine) renin-angiotensin system (RAS) is an evolutionarily 
conserved enzyme system that plays a key role in circulatory homeostasis. In 
phylogenetic analyses, components of this RAS are found in primitive chordates 
(emerging approximately 550 million years ago) with a complete system evident by the 
time of the bony-fish/tetrapod divergence (approximately 400 million years ago) and 
evidence of horizontal transfer of RAS components to bacteria from ancestral non-
vertebrate species (Fournier et al. 2012). 
In the endocrine RAS, hepatically derived angiotensinogen is cleaved by the aspartyl 
protease renin of renal juxtaglomerular origin to yield the inactive decapeptide 
angiotensin I (AngI). AngI is then, in turn, cleaved by angiotensin I converting enzyme 
(ACE) to produce the octapeptide angiotensin II (AngII). ACE is a zinc metallopeptidase 
present both in circulating and endothelially bound forms, with particularly high 
expression on pulmonary endothelial cells. The AngII it produces is regarded as the 
most important effector protein of the RAS. AngII binding at the Angiotensin II Type 1 
receptor (AT1R) on vascular endothelium causes vasoconstriction whilst at the adrenal 
glomerulosa it stimulates the secretion of aldosterone and subsequent reabsorption of 
sodium and water in the renal tubules. AngII also has a direct sodium-reabsorptive 
effect in the kidney, and acts in the brain to stimulate thirst (Fitzsimons 1998). Finally, 
ACE degrades the vasodilator bradykinin thus amplifying the vasoconstrictor effects of 
AngII. The cumulative effect of these actions is to increase blood pressure, and the 
RAS is viewed as one of the most important modulators of the systemic circulatory 
system. 
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Figure 1. The endocrine RAS. Angiotensinogen released from the liver is converted to AngI by renin 
(of renal origin). Angiotensin I converting enzyme (ACE) converts AngI to AngII in the pulmonary 
bed which then acts at the vascular endothelium to cause vasoconstriction, the brain to cause 
thirst and the kidney to increase Na
+
 reabsorption. AngII also acts at the adrenal to cause 
aldosterone release which then acts at the kidney to increase Na
+
 and H2O reabsorption. The 
combined effect of these actions is to increase circulatory volume and blood pressure. 
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1.2. The extended RAS  
Over the last two decades, our understanding of the classical RAS has been extended 
by the discovery of additional components and their actions. The metabolic derivatives 
of AngII have been identified as important effector peptides in their own right. AngII is 
degraded to the heptapeptide des-Asp1–AngII, also known as Angiotensin III (AngIII) by 
vascular and erythrocyte glutamyl aminopeptidase A (Ward et al. 1990; Chauvel et al. 
1994) and subsequently to the hexapeptide des-Asp1, des-Arg2-AngII, also known as  
angiotensin IV (AngIV) by alanyl aminopeptidase N. Both AngIII and AngIV are active 
peptides with similar (but less potent) circulatory effects to those of AngII. Angiotensin 
(1-12) (Ang(1-12)) is a recently discovered peptide with a two amino acid extension at 
the C-terminus of AngI (Nagata et al. 2006) which is formed independently of renin 
action but is thought to be a peptide precursor of AngII. 
Further, there is redundancy in the conversion of AngI to AngII, with numerous other 
enzymes carrying out the same cleavage. Chymase catalyses the same reaction in 
many tissues (Singh, Le, et al. 2008; Cristovam et al. 2008; Tom et al. 2003) whilst 
members of the caspase family of proteins and cathepsin G also perform this function 
(Urata et al. 1990; Naruse & Inagami 1982; Lorenz 2010). 
Alongside the AngI-ACE-AngII-AT1R pathway, a second seemingly counter-regulatory 
arm of the endocrine RAS has been identified. ACE2 is a homologue of ACE and yields 
the heptapeptide angiotensin (1-7) (Ang(1-7)) from AngII (Vickers et al. 2002) whilst 
also degrading AngI to the inactive nonapeptide angiotensin (1-9) (Ang(1-9)). Ang(1-9) 
is then converted to Ang(1-7) by ACE (Tipnis et al. 2000). Ang(1-7) acts at the Mas 
receptor to produce effects that are largely opposite to those mediated by the AT1R 
(Santos et al. 2013a) thus acting as a counterbalance to the classical system. A further 
counter-regulatory pathway is effected by an alternative AngII receptor, the Angiotensin 
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II Type 2 receptor (AT2R) whose role, while less well understood than that of the AT1R, 
seems widely to be in opposition (Carey & Siragy 2003). 
Along with the discovery of several novel components of the RAS, additional actions of 
existing components are also being elucidated. Most notable of these was the 
discovery that both prorenin and renin can act as ligands at the recently identified 
(Pro)renin receptor, implying that prorenin and renin can exert effects independent of 
AngII (Nguyen et al. 2002; Nguyen et al. 1996). The complexity of the RAS continues to 
increase with the identification of further components, such as Angiotensin A and 
Alamandine (Carey 2013; Carey & Siragy 2003).  
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Figure 2. The extended RAS. As well as its action at AT1R, AngII acts at AT2R to have largely 
counter active effects. AngII is metabolised to AngIII then AngIV, both metabolically active 
peptides. AngIV acts at both AT4R and AT1R whilst AngIII acts predominantly at AT1R and AT2R. 
Further counter-regulation is achieved through the action of Ang(1-7), formed by ACE2 metabolism 
of AngII, at the Mas receptor. There is redundancy in the action of ACE; chymase, cathepsin G and 
caspase can all catalyse the same reactions. The recent discovery of renin and pro renin action at 
the (pro)renin receptor provides an action of the RAS independent of Angiotensin peptide action. 
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1.3. RAS receptors 
AngII exerts its effect through action at a set of AngII receptors. There are three main 
receptors in humans; AT1R, AT2R and AT4R. The latter binds AngIV with high affinity 
but AngII and AngIII with low affinity and is also capable of binding multiple other 
peptides. The receptor has been identified as an insulin-regulated membrane 
aminopeptidase (IRAP) (Chai et al. 2004; Demaegdt et al. 2009) and its expression 
confirmed in various mammalian tissues including adrenal gland, bladder, colon, 
kidney, heart, prostate, brain and spinal cord (Zhuo et al. 2013; Wright et al. 1995). 
However, the physiological roles of AT4R are not well understood. Further, its ligand 
(AngIV) mediates many of its known effects through AT1R (Yang et al. 2010; Yang et al. 
2008) or AT2R (Vinh, Widdop, Drummond, et al. 2008; Vinh, Widdop, Chai, et al. 2008). 
By far the more abundant receptors are the AT1R and AT2R. Both are G protein 
coupled seven hydrophobic transmembrane glycoprotein receptors which share 34% 
sequence homology. The AT1R is ubiquitous, whilst the AT2R is being identified in an 
increasing number of tissue types, although its mechanisms of action are less well 
understood. 
1.3.1. AT1R 
Although the AT1R has been sequenced, its crystal structure has not been solved 
(Matsoukas et al. 2013). That said, a combination of computer modelling and AngII 
binding studies have elucidated the relative binding affinity of ligands at AT1R as AngII 
> AngIII > AngIV > Ang(1-7) (Bosnyak et al. 2011). Ligand binding at AT1R leads to 
activation of several signalling cascades. These can roughly be divided into G protein 
coupled and non-G protein coupled pathways. On AngII binding, AT1R interacts with G 
protein complexes which activate downstream effector peptides including protein 
kinase C (PKC), phospholipase C (PLC), phospholipase A2 (PLA2) and phospholipase 
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D (PLD) (Ushio-Fukai et al. 1999). Activation of PLC seems of particular importance, 
since it leads to inositol-1,4,5-triphosphate (IP3) generation within seconds (along with 
diacyl glycerol, DAG) which acts on its receptor (IP3R) on endoplasmic reticulum to 
cause Ca2+ release (Marks 1997). Other G protein linked signalling pathways enhance 
growth, migration and inflammation related pathways including PKC mediated 
activation of NAD(P)H oxidase (Nox)- a major source of cellular reactive oxygen 
species (ROS) (Montezano et al. 2014; Dikalov & Nazarewicz 2013; Bataller et al. 
2003). 
Along with G proteins, AT1Rs also activate the mitogen-activated protein kinases 
(MAPKs) which play essential roles in gene expression, protein synthesis, metabolism 
and growth (Palomeque et al. 2009; Smith et al. 1999). This involves the ERK 1/2, JNK 
and p38 MAPK pathways, all of which can be activated downstream of AT1R (Mehta & 
Griendling 2007). Add to these pathways the receptor and non-receptor tyrosine kinase 
pathways, and the complexity of AT1R signalling becomes apparent (Yaghini et al. 
2007; Gasparo et al. 2000; Hunyady & Catt 2006; Wang et al. 2004). 
Downstream of these signalling cascades, AT1R activation leads to cellular changes 
stimulating growth, inflammation, oxidative stress and vasoconstriction (Cassis et al. 
2010). 
1.3.2. AT2R 
As well as binding AT1R, AngII binds AT2R with high affinity and in fact displays slight 
preferential selectivity for AT2R (Bosnyak et al. 2011). The affinity binding hierarchy of 
AT2R follows AngII > AngIII > AngIV > Ang-(1-7), with all showing selectivity for AT2R 
over AT1R (Bosnyak et al. 2011). The AT2R is ubiquitously expressed in foetal tissue 
but is down-regulated after birth (Nahmias & Strosberg 1995) with evidence suggesting 
24 
 
it may be up-regulated in disease states; in cadaveric studies of human heart failure the 
relative abundance of AT2R is increased (Haywood et al. 1997). Signalling pathways of 
the AT2R are poorly described but there is evidence that stimulation of AT2R triggers an 
autocrine cascade including tyrosine phosphatase, serine/threonine phosphatase and 
bradykinin/nitric oxide/cyclic GMP axis activation (Carey et al. 2000; Siragy 2000). 
Interestingly, evidence suggests that AT2R can directly bind to (and inhibit) the AT1R, 
an action which does not necessarily depend on AT2R activation (AbdAlla et al. 2001). 
1.3.3. Mas receptor 
Ang(1-7) displays the lowest binding affinity at AT1R and AT2R of all the established 
RAS ligands (Bosnyak et al. 2011), instead exerting its biological influence through 
action at the Mas receptor. Like the other AngII receptors, Mas is a G protein coupled 
receptor. It is encoded by the MAS oncogene, and expression has been proven in most 
tissues (Xu et al. 2011; Metzger et al. 1995; Alenina et al. 2008). A growing evidence 
base suggests that the ACE2/Ang(1-7)/Mas axis counteracts most of the effects of the 
ACE/AngII/AT1R axis (Ferreira & Santos 2005). In cardiac and endothelial tissue, Mas 
activation causes vasodilatation possibly through PI3-AKT signaling to cause release of 
NO and prostaglandins (Walkyria Sampaio et al. 2007; Santos et al. 2006), whilst in the 
kidney, expression is increased in renal ischaemia (Zimmerman & Burns 2012) and 
counteracts MAPK singalling at AT1R (W Sampaio et al. 2007). With evidence for 
antifibrotic and antiproliferative effects of Mas activation accumulating (Wu et al. 2014; 
Santos et al. 2013b) the position of the ACE2/Ang(1-7)/Mas axis as a counter 
regulatory mechanism to AT1R activation strengthens.  
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1.4. Tissue RAS 
As well as the circulating RAS, independently regulated RAS exist and operate at the 
tissue level (Bader & Ganten 2008; Velez 2009). Such RAS appear ubiquitous, having 
been identified in (amongst many other organs and tissues) kidneys, liver, spleen, 
pancreas, heart, lung, adrenal glands, brain, immune system and skeletal muscle 
(Montgomery et al. 2003; Paul et al. 2006; Jones & Woods 2003; Sakai & Sigmund 
2005; Bader & Ganten 2008; Campbell & Habener 1987; Campbell & Habener 1986). 
The concept of a tissue RAS gained credence with the identification of RAS component 
expression in tissues distant to their classical site of production or action, such as the 
‘renal’ enzyme renin in brain tissues (Ganten et al. 1971). The mapping of AngII 
receptors at sites in the brain that cannot be reached by circulating AngII due to the 
blood-brain barrier (Phillips et al. 1977; Ganten et al. 1971) further supported the idea 
of a sequestered tissue RAS. Similarly, in the kidney the localisation of renin 
messenger RNA (mRNA) and protein outwith juxtaglomerular cells and within the 
proximal tubules and the collecting duct system (Moe et al. 1993), together with 
confirmation of angiotensinogen and ACE expression within the kidney (Schulz et al. 
1988; Gomez et al. 1988), pointed to a renal RAS that could function independently of 
the circulating system. 
The completeness of tissue RAS differs between organs. Some tissues have the full 
enzymatic cascade, including tissue specific enzyme isoforms (Sinn & Sigmund 2000) 
producing biologically active AngII, AngIII, Ang(1-7) and AngIV, whilst others depend on 
the uptake of key components from the circulation (van Kesteren et al. 1997; Krop & 
Danser 2008; Danser 2003). For example, in the heart, AT1R and AT2R are expressed 
but local AngII production is dependent on the uptake of renin from the circulation 
(Peters et al. 2002) or renin released from cardiac mast cells (Mackins et al. 2006). 
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Within the tissue on a cellular level, AngII produced intracellularly can be secreted to 
act via plasma membrane AngII receptors of neighbouring cells (paracrine actions) or 
on the synthesising cell itself (autocrine action) (Inagami et al. 1990; Inagami et al. 
1986; Sadoshima et al. 1993; Vila-Porcile & Corvol 1998). In this way, the RAS can 
influence single cell activity or local tissue activity, leading to whole organ physiological 
changes.  
The roles of tissue RAS are still being elucidated but are extensive. AngII acts as a 
cellular growth factor in vascular and cardiac tissues (Imanishi et al. 2004; Vukelic & 
Griendling 2014) whilst causing hypertrophy in cardiac and skeletal muscle (AngII being 
essential for transforming load into growth) (Gordon et al. 2001; Lijnen & Petrov 1999; 
Sadoshima et al. 1993). It regulates fibroblast function, with a pro-fibrotic role proven in 
kidney, liver, lung and cardiac tissue amongst others (Granzow et al. 2014; Mezzano et 
al. 2001; Wynn 2008; Sadoshima & Izumo 1993; Königshoff et al. 2007) and influences 
cell differentiation such as that of preadipocyte to adipocyte (Darimont et al. 1994; 
Janke et al. 2002) as well as vascular and bone progenitor cells (Roks et al. 2011; 
Durik et al. 2012). AngII also regulates cell cycle, being an important pro-apoptotic 
factor in cardiac and alveolar cells (Wang et al. 1999; Papp et al. 2002; Schröder et al. 
2006). These actions are predominantly mediated via the AT1R. Action of AngII at the 
AT2R seem broadly antagonistic to these effects; cardiac hypertrophy is inhibited 
(Jones et al. 2004), it mediates antifibrotic signalling (Schulman & Raij 2008) and, in the 
kidney, vasodilatation and natiuresis is stimulated (Carey et al. 2000; Nouet & Nahmias 
2000). 
These multiple cellular actions of tissue RAS explain how the accepted benefits of ACE 
inhibitor and AngII receptor blocker medication in hypertension, cardiovascular disease 
and diabetes appear to be independent of their blood pressure lowering actions (Pfeffer 
27 
 
et al. 1992; Dahlöf et al. 1998; Park et al. 2000; Opie 2001). Modulating tissue RAS 
function therefore offers a potentially powerful way of counteracting organ dysfunction.  
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1.5. Intracrine RAS 
The paracrine and autocrine actions of AngII are mediated by action at the plasma 
membrane receptors. However, over the last 20 years, evidence of intracellular AngII 
activity has accumulated. The existence of intracellular AngII receptors emerged with 
nuclear AT1Rs demonstrated in the renal cortex and medulla, vascular smooth muscle, 
cardiomyocytes and hepatocytes amongst others (Julia L Cook et al. 2006; Eggena et 
al. 1993; Pendergrass et al. 2006; Tadevosyan et al. 2010). Intracellular microinjection 
of AngII in proximal tubule cells caused an increase in intracellular Ca2+ (iCa2+) peaking 
at 30 seconds proving these receptors to be functional (Zhuo et al. 2006). This effect 
was attributed to intracellular AngII action since blockade of plasma membrane 
receptors with losartan (a specific AT1R antagonist) had no impact whilst microinjection 
of AngII and losartan abolished the iCa2+ response (Zhuo, Li, et al. 2006). Since then, 
AngII binding at the nucleus has also been shown to induce ROS production within the 
nucleus (Gwathmey et al. 2010; Pendergrass et al. 2009) and directly induce 
transcription of factors including transforming growth factor beta (TGF-β), macrophage 
chemoattractant protein-1 (MCP-1) (X. C. Li and Zhuo 2008b), cyclic AMP response 
element binding protein (CREB) (Julia L Cook et al. 2006) and platelet derived growth 
factor (PDGF) (J. L. Cook, Zhang, and Re 2001; Julia L Cook et al. 2002), NFκB 
(Tadevosyan et al. 2010), as well as RAS components such as renin and 
angiotensinogen (Eggena et al. 1993). 
How AngII, its receptors and other components of the RAS come to reside 
intracellularly is a matter of debate. There is abundant evidence for AngII-AT1R 
complex internalisation following binding on the plasma membrane (Zhuo & Li 2007; Li 
et al. 2009; Li et al. 2007; Li & Zhuo 2008) with the suggestion that it is these 
internalised components that form the ‘intracellular’ RAS. Certainly, there is evidence of 
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ongoing receptor activity in endocytosed vesicles (Murphy et al. 2009; Cook & Re 
2012), and also of AngII ‘spill’ into the cytoplasm (Cho et al. 2003; Brown et al. 1982). 
Alternatively, AngII may be produced entirely within the cell and act independently of 
plasma membrane receptors. In support of this, in neonatal rat ventricular myocytes 
(NRVMs) exposed to high glucose serum, AngII accumulates intracellularly despite 
blockade of plasma membrane AT1R with candesartan (Singh, Baker, et al. 2008; 
Singh et al. 2007). Further, the components of the RAS required to produce AngII have 
all been localised within single cells (Naruse et al. 1982; Inagami et al. 1986; Inagami et 
al. 1990). A truncated renin transcript lacking the coding sequence to target the protein 
to the secretory pathway (exon(1-9)) has been identified and shown to produce a renin 
isoform that remains in the cytoplasm (Peters 2002; Lavoie et al. 2004; Lee-Kirsch et 
al. 1999; Sinn & Sigmund 2000) whilst angiotensinogen mRNA expression has been 
found in multiple tissues (Campbell & Habener 1987; Campbell & Habener 1989; 
Campbell & Habener 1986; Tadevosyan et al. 2010; Dzau et al. 1987; Lee et al. 1987) 
including an isoform that can be retained within the cell depending on glycosylation 
state (Sherrod et al. 2005). Finally, transfecting cells with a non-secreted form of 
angiotensinogen causes an increase in intracellular AngII, proving potential for 
intracrine AngII generation (Cook & Re 2009). 
It appears that the control of intracellular RAS is independent of circulating systems. 
Adrenal intracellular renin is increased in response to elevated serum potassium 
whereas circulating renin is decreased (Nakamaru et al. 1985), whilst high glucose 
causes a 10-fold increase in intracellular ACE but has no effect on extracellular ACE 
(Cristovam et al. 2008). Such an enclosed, internally regulated system would offer an 
elegant way of modulating cell activity.  
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1.6. RAS and physical performance 
Tissue RAS appear to influence aspects of physical performance. Whilst polymorphic 
variations exist in the genes of many of the RAS components, the most studied is that 
found in the human ACE gene. The absence (deletion [D]) rather than the presence 
(insertion [I]) of a 287-base pair Alu repeat sequence within intron 16 of the ACE gene 
is associated with higher circulating plasma (Rigat et al. 1990) and tissue (Costerousse 
et al. 1993; Danser et al. 1995) ACE activity. Numerous studies have shown an 
association of the I allele with endurance exercise. An excess of the I allele has been 
found in distance runners (Myerson et al. 1999), elite ultra-long distance swimmers 
(Tsianos et al. 2004) and Olympic rowers (Gayagay et al. 1998). This relationship 
seems to relate to metabolic efficiency; training-related improvement in efficiency of 
muscle contraction in Caucasian military recruits measured by delta efficiency (DE; 
percentage ratio of change in work performed per minute to the change in energy 
expended per minute) was strongly genotype dependent, with only II individuals (and 
not DD) showing a significant increase in DE (Williams et al. 2000). Furthermore, 
amongst Caucasian military recruits undergoing training, the I allele was associated 
with relative conservation of fat stores (Montgomery et al. 1999). As one would expect, 
this greater metabolic efficiency seems to translate to better performance in hypoxic 
conditions (Tsianos et al. 2006; Montgomery et al. 1998; Kalson et al. 2009; Tsianos et 
al. 2005). British elite mountaineers demonstrate an allele skew towards the I allele 
(Woods & Montgomery 2001), whilst in 139 mountaineers attempting to ascend to 
8000m, maximum altitude achieved was significantly associated with the same allele 
(Thompson et al. 2007).  
These data seem to hint at a role for tissue and intracellular RAS in modulating cellular 
energetics.  
31 
 
1.7. RAS and cellular energetics 
Some of the first evidence of a role for RAS in cellular energetics came from studies of 
tissue oxygen uptake in organs perfused with AngII. AngII caused a dose dependent 
increase in oxygen uptake in the perfused rat hindlimb (Colquhoun et al. 1988) and liver 
lobules (Matsumura et al. 1992) whilst in the kidney AngII perfusion was associated 
with increased oxygen consumption (QO2) and reduction in the renal efficiency for 
transporting sodium (QO2/TNa
+) (Welch et al. 2005; Laycock et al. 1998; Deng et al. 
2005). More recently it has been shown that inhibition of RAS (with combined ACE 
inhibition and AT1R antagonism) can normalise QO2/TNa
+ (Deng et al. 2009). In cardiac 
ischaemia-reperfusion injury models, higher ACE expression impairs myocardial 
tolerance to ischaemia (Messadi et al. 2010) whilst ACE inhibition potentiates the 
ischaemia-sparing effect of cardiac pre-conditioning (Miki et al. 1996; Jaberansari et al. 
2001). Meanwhile inhibition of the RAS in animal models of heart failure maintains 
myocardial maximal oxidative capacity and adenosine triphosphate (ATP) production 
(Sanbe et al. 1995). 
There is evidence that these effects relate to reactive oxygen species (ROS) 
production. In vascular smooth muscle cells (VSMC) ROS were released within 
minutes of exposure to AngII (Sorescu & Griendling 2002) whilst in cardiomyocytes 
from diabetic rats, increased AngII levels were associated with increased superoxide 
production (Singh, Le, et al. 2008). Causation is suggested by data showing renin 
inhibition to prevent the ROS accumulation. There are two major sites of ROS 
production in most cell types; the NAD(P)H oxidases (the Nox protein family) and 
mitochondria. Whilst pathways of AngII mediated signalling via cell membrane or 
cytosolic Nox are described (Dikalov & Nazarewicz 2013), a direct action of AngII on 
mitochondria has not be ruled out.  
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1.8. Mitochondrial physiology 
Mitochondria are the primary sites of ‘energy currency’ production (ATP synthesis). 
Each mitochondrion consists of phospholipid outer and inner membranes separated by 
an intermembrane space. The inner membrane is folded into ridges (or cristae) and 
bounds the mitochondrial matrix. Within the inner mitochondrial membrane sit the 
protein complexes of the electron transport system (ETS) which drives ATP synthesis 
through oxidative phosphorylation (OXPHOS). 
1.8.1. The electron transport system 
The ETS is classically described as consisting of four separate complexes (complexes 
I-IV) and two mobile electron carriers (coenzyme Q and cytochrome C) along with ATP 
synthase (sometimes referred to as complex V). Each complex is a large protein 
aggregate composed of multiple subunits encoded by both mitochondrial and nuclear 
DNA (other than complex II which is encoded by nuclear DNA only). Electrons from 
reduced nicotinamide adenine dinucleotide (NADH) enter the ETS at complex I whilst 
reduced flavin adenine dinucleotide (FADH2) donates electrons to complex II. As 
electrons pass through complexes I, III and IV, a drop in their redox potential is coupled 
to the extrusion of protons from the matrix across the inner mitochondrial membrane to 
the intermembrane space generating an electrochemical gradient. Complex IV is the 
terminal oxidase of the mitochondrial ETS, reducing oxygen with four electrons to 
produce two molecules of water. The return of the hydrogen ions across the membrane 
at complex V drives the synthesis of ATP.  
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Figure 3. The electron transfer system (ETS). Electrons donated from NADH are accepted by 
complex I and those donated from FADH2 are accepted by complex II. Electrons pass through 
complexes III and IV with extrusion of protons (H
+
) at complexes I, III and IV. The proton motive 
force generated is then used by ATPase to produce ATP. Q; coenzyme Q, C; cytochrome C.  
 
It is important to note this representation of the ETS is a simplification. More accurately 
it consists of six rather than four protein aggregates, with electron-transferring 
flavoprotein:ubiquinone oxoreductase (ETF:QO) and glycerophosphate dehydrogenase 
(GCPD) both residing in the inner mitochondrial membrane and contributing electrons 
to the ubiquinone pool and in so doing play a significant role in OXPHOS. Crucially, 
these complexes do not form a chain. Rather, electrons from complex I and complex II 
are both carried by coenzyme Q to complex III. Thus a convergent structure of electron 
flow to the ‘Q-junction’ in the ETS can be described (Gnaiger 2009) (Fig. 4). From there 
they pass through complex III to IV via cytochrome C. The tight coupling between 
electron transport and proton extrusions means that the rate of mitochondrial oxygen 
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consumption is an accurate measure of the total proton current (Brand & Nicholls 
2011). 
 
Figure 4. The convergent structure of electron flow. Electrons donated to complex I and complex II 
both flow to complex III via coenzyme Q (Q). From there electrons are ferried to complex IV by 
cytochrome C (C). 
1.8.2. Metabolic substrates 
The electrons required to support OXPHOS are donated by reducing equivalents 
produced within the cell by metabolism of energy substrates. Through glycolysis, 
glucose is converted to pyruvate in the cytosol which is transported to the mitochondrial 
matrix where it is converted to acetyl-CoA by pyruvate dehydrogenase and enters the 
tricarboxylic acid (TCA) cycle (also known as citric acid or Krebs cycle) producing three 
NADH molecules and one FADH2 molecule. 
Fatty acids are metabolised first in the cytosol producing acyl-CoA which is transported 
to the mitochondrial matrix whereupon it undergoes sequential oxidation of its carbon 
double bonds (β-oxidation). Each carbon bond oxidised produces one molecule each of 
NADH and FADH2 which are fed into the ETS, along with one molecule of acetyl-CoA 
which enters the TCA cycle. 
Amino acids can also act as substrates. Following removal of the amino group 
(deamination) the carbon skeletons are used to produce metabolic intermediates of the 
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TCA cycle. Amino acids that are degraded to acetyl-CoA or acetoacetyl-CoA are 
termed ketogenic because they can lead to ketone body production, whilst those that 
are metabolised to form pyruvate, α-ketoglutarate, succinyl-CoA, fumarate or 
oxaloacetate are termed glucogenic amino acids. 
1.8.3. Mitochondrial respiration, coupling and efficiency 
1.8.3.1. Respiratory states 
The conventional description of mitochondrial bioenergetics was made by Britton 
Chance and Ron Williams in 1956 (Chance & Williams 1956) as a way of describing the 
various activity states of the ETS during experimental in vitro respiration. Depending on 
the presence of respiratory substrates and availability of ADP, four states can be 
described (1,2,3 and 4). State 1 refers to mitochondria respiring on their endogenous 
substrates in the presence of oxygen but the absence of supplemented ADP. Once 
these endogenous substrates are oxidised, mitochondria enter State 2, respiring at a 
residual or basal rate in compensation for proton leak across the inner mitochondrial 
membrane. State 3 is the rate of respiration achieved in the presence of saturating 
concentrations of substrates and ADP and is close to maximal oxidative capacity. State 
4 describes the resting state of mitochondria, achieved following consumption of the 
exogenous ADP. 
By measuring the rate of oxygen consumption during these states of activity, 
statements regarding mitochondrial respiratory capacity and efficiency can be made. 
1.8.3.2. LEAK respiration 
LEAK respiration refers to the imperfect coupling of proton movement and ATP 
generation. All mitochondria display endogenous proton leak across their inner 
membranes (Nicholls 1977). In the resting state, dissipation of the membrane potential 
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caused by this proton movement causes activation of the ETS in order to maintain a 
high membrane potential -reflected in ongoing oxygen consumption in the absence of 
ADP. 
There are several suggested mechanisms to explain leak. Proton slip refers to a 
property of the proton pumps (complexes I, III and IV) whereby protons slip back to the 
matrix side of the membrane instead of across it during electron transfer. In addition, 
some protons are moved across the membrane independent of OXPHOS in the cycling 
of Ca2+ (Nicholls 2005) and the shuttling of ATP and ADP by adenine nucleotide 
translocase (ANT) (Brand et al. 2005). 
There is also evidence that specific proteins, known as uncoupling proteins, contribute 
to LEAK respiration. In brown fat, uncoupling protein 1 (UCP1) functions to dissipate 
membrane potential with the energy that is derived from the oxidised substrates 
released as heat (Nedergaard & Cannon 2010). The primary role of UCP1 seems to be 
thermogenesis, though regulation of ROS production has also been suggested (Clarke 
& Porter 2013; Dlasková et al. 2010). Since UCP1 was identified, uncoupling functions 
of other proteins have been suggested (most notably UCP2 and UCP3). These proteins 
are all members of the anion carrier protein family and are located in the inner 
mitochondrial membrane. In vitro experiments have suggested that they can uncouple 
OXPHOS when suitably activated by superoxide and alkenals (Echtay et al. 2002; 
Brand et al. 2004; Brand & Esteves 2005). A role in controlling ROS production, and 
even ROS signalling with so called ‘mild uncoupling’ has gained credence (Echtay 
2007; Divakaruni & Brand 2011), though the physiological credibility of this theory has 
recently been questioned (Shabalina & Nedergaard 2011). 
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1.8.3.3. Mitochondrial ROS 
Whilst the vast majority of O2 within in a cell is converted to H2O at complex IV of the 
ETS, approximately 1-2% of cellular O2 is consumed by the production of reactive 
oxygen species (ROS). ROS are produced when electrons are donated to O2 to form 
superoxide (O2
-). This can occur at various locations in the cell such as cell membrane 
NAD(P)H oxidase or cytosolic xanthine oxidase (Iuchi et al. 2003) but mitochondria also 
represent a major source of ROS (Chandel et al. 1998; Jastroch et al. 2010). Within 
mitochondria, ROS are predominantly produced at complex I and complex III (Turrens 
2003; Li et al. 1999) though under certain pathological conditions, complex II can 
contribute to ROS production by directing electrons though complex I rather than 
complex III (‘reverse electron transport’) (Chouchani et al. 2014; Grivennikova & 
Vinogradov 2006). Other mitochondrial sources of ROS include matrix enzymes 
(Messner 2002; Starkov et al. 2004), outer membrane monoaminoxidases (Cadenas & 
Davies 2000) and mitochondrial NOS uncoupling (Brodsky et al. 2002). 
Produced at ETS complexes, O2
- can be then be released to either side of the inner 
mitochondrial membrane (Muller et al. 2004) where it is rapidly converted to hydrogen 
peroxide (H2O2) either by abundant superoxide dismutase (mn-SOD) in the matrix 
(Andreyev et al. 2005) or copper/zinc containing SOD (Cu,Zn-SOD) in the 
intermembrane space (Okado-Matsumoto & Fridovich 2001). H2O2 diffuses freely 
across the outer mitochondrial membrane and into cytosol. 
Conditions of excess ROS production (oxidative stress) are linked to a multitude of 
disease processes including cardiovascular diseases, diabetes, chronic kidney disease 
and cancer (Rochette et al. 2014; Csányi & Miller 2014; Gwinner & Gröne 2000; Cerutti 
& Trump 1991). However, under non-pathological conditions ROS act as signalling 
molecules, oxidising redox-sensitive phosphatases/kinases and modifying 
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phosphorylation status of transcription factors or receptors (de Cavanagh et al. 2007; 
Suzuki et al. 1997). These ROS signals are suggested to play important roles in 
metabolism, cell differentiation, the stress response and aging (Hou et al. 2014). 
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1.9. The mitochondrial environment 
Mitochondria exert an influence on, and are influenced by, their surrounding cellular 
environment (Raturi & Simmen 2013). Rather than operating as isolated units, they 
interact with each other and neighbouring organelles. The significance of the interaction 
between mitochondria and endoplasmic reticulum (ER) is of increasing interest 
(Hayashi et al. 2009; Raturi & Simmen 2013; Schon & Area-Gomez 2013). 
Areas of the ER in close contact with the outer mitochondrial membrane (OMM) are 
termed the mitochondria-associated membrane (MAM). It is estimated that between 5-
20% of mitochondrial membrane is in close contact with the ER at any time (Rizzuto et 
al. 1998). These areas appear to be regulated separately to the rest of the ER, with 
local enrichment in functionally diverse enzymes, involved in lipid transport, Ca2+ 
handling and other signal transductions (Hayashi et al. 2009; Bravo et al. 2011). These 
proteins can interact directly with the OMM since the distance between MAM and 
mitochondrion can be as little as 10-20 nm (Csordás et al. 2006). Communication 
between mitochondria and MAM has been shown to influence lipid transport (Fujimoto 
& Hayashi 2011), Ca2+ signalling and homeostasis (Szabadkai & Duchen 2008), 
mitochondrial fission (Marchi et al. 2014) energy metabolism (Cárdenas et al. 2010) 
and cellular survival (Giacomello et al. 2007). 
Ca2+ signalling at the MAM is perhaps best described (Voelker 2005; Vance 2003; 
Rizzuto et al. 2004; Hajnóczky et al. 2003). In the ER, stimulation of IP3R by IP3 leads 
to a massive release of Ca2+ (Fieni et al. 2012; Kirichok et al. 2004; Wojtczak et al. 
2010). IP3R are highly compartmentalised in MAM (Mendes et al. 2005) leading to 
microdomains of high [Ca2+] when stimulated. Direct interaction of IP3R with the voltage 
dependent anion channel (VDAC) of the OMM leads to Ca2+ uptake (Szabadkai et al. 
2006) whilst the high [Ca2+] activates the Ca2+ uniporter of the IMM enabling transfer of 
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Ca2+ into the matrix (Wojtczak et al. 2010; Szabadkai & Duchen 2008; Rizzuto et al. 
2009). 
Increasing [Ca2+] in the mitochondrial matrix can influence bioenergetics in various 
ways. Three TCA cycle enzymes (pyruvate dehydrogenase, α-ketoglutarate 
dehydrogensase and isocitrate dehydrogenase) have Ca2+ binding sites that regulate 
their activity (Rutter & Denton 1988; McCormack & Denton 1979; Denton 2009; Denton 
et al. 1980) whilst both glutamate and aspartate carriers are Ca2+ sensitive (Lasorsa et 
al. 2003). Ca2+ also modulates intramitochondrial antioxidant levels (Hopper et al. 
2006). Therefore, IP3R activation on the MAM can directly influence mitochondrial 
function. 
The importance of MAM-mitochondrial interactions is only just being elucidated. 
Disruption of these interactions has been implicated in Alzheimer’s and other 
neurodegenerative diseases (Schon & Area-Gomez 2013), insulin dependent diabetes 
(Tubbs et al. 2014), cardiac ischaemia-reperfusion injury (Paillard et al. 2013), 
myopathies (Eisner et al. 2013) and the pathogenesis of some viruses (Vance 2014).  
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1.10. RAS and mitochondria 
Evidence that RAS influence aspects of mitochondrial function does exist, but is limited 
and yet to be drawn into a coherent narrative. Studies linking RAS and mitochondrial 
dysfunction can be broadly separated into those suggesting an effect on biogenesis 
and those implying an alteration in respiratory function. 
When muscle is exposed to AngII in either cell culture or animal models, there is a 
decrease in mitochondrial number and an associated decrease in markers of 
mitochondrial biogenesis (Mitsuishi et al. 2009). Examination of the cardiac 
transcriptome of mice exposed to AngII revealed a decreased expression of important 
mitochondrial mRNAs including those coding for proteins integral to the ETS, beta 
oxidation pathway and the TCA cycle (Larkin et al. 2004). Meanwhile, chronic 
antagonism of RAS in mice (by ACE inhibition or AngII receptor blockade/knockout) 
prevents the recognised age related decrease in mitochondrial number in both kidney 
(Ferder et al. 2002; de Cavanagh et al. 2003) and liver (de Cavanagh, Flores, et al. 
2008; Cassis et al. 2010) whilst AngII receptor blockade induces mitochondrial 
biogenesis in rat hearts (Mervaala et al. 2010). These data suggest RAS operates 
through nuclear regulatory pathways to influence mitochondrial number and ETS 
protein content.  
There is evidence that the RAS might affect mitochondrial respiration more directly. 
Mitochondria isolated from bovine endothelial cells cultured in the presence of AngII 
display an increased State 4 respiration and decreased State 3 respiration along with a 
decreased resting mitochondrial membrane potential (Doughan et al. 2008). These 
cells also showed elevated levels of H2O2. Similarly, increased ROS levels were 
demonstrated in VSMCs exposed to AngII in association with reduction in mitochondrial 
membrane potential, an effect seemingly caused by interaction with mitochondrial ATP 
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sensitive K+ channels (Kimura et al. 2005). In mitochondria isolated from hindlimb 
skeletal muscle of mice dosed with AngII for 7 days, again there was an increased 
State 4 respiration (Inoue et al. 2012). In these mitochondria, there was significant 
impairment of respiration through complex I and complex III together with an increased 
O2
- production and expression of UCP3 (Inoue et al. 2012). Meanwhile, inhibition of the 
RAS with a non-antihypertensive dose of the ACE-inhibitor enalapril increased ETS 
enzyme activities and mitochondrial antioxidant levels in spontaneously hypertensive 
rats (Piotrkowski et al. 2009). 
Many of these effects appear to be orchestrated by action of AngII at the AT1R. In 
cardiac mitochondria isolated from mouse hearts subjected to acute ischaemia, prior 
perfusion with valsartan (AT1R antagonist) preserved mitochondrial function (higher 
State 3 and State 4 respiration, preserved mitochondrial membrane potential, higher 
ATP/ADP ratio and shorter phosphorylation lag time) (Monteiro et al. 2005). Similarly 
AT1R blockade with losartan preserves renal mitochondrial function in the 
spontaneously hypertensive rat (de Cavanagh et al. 2006) and streptozotocin-induced 
Type 1 diabetic rat – an effect associated with increased UCP2 expression and 
elevated cytochrome C activity (de Cavanagh, Ferder, et al. 2008). 
All of these suggested effects of AngII could be mediated by activation of AngII 
receptors on the cell surface or nuclear membrane, with downstream signalling 
pathways influencing gene transcription or enzyme activity (Dikalova et al. 2010; 
Sachse & Wolf 2007; Zhang et al. 2007; Spät & Hunyady 2004; Hunyady & Catt 2006). 
However, there is evidence to suggest AngII may also act directly on mitochondria. 
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1.11. Mitochondrial RAS 
The evidence to support a RAS operating within or in close association with 
mitochondria is gathered from studies spanning the last 40 years. The first evidence 
came from studies using radiolabelled AngII to identify intracellular sites of action. 
Exogenously administered 3H-labelled AngII trafficked to the surface of rodent cardiac 
mitochondria (Robertson & Khairallah 1971) whilst radioiodinated AngII (125I-AngII) 
bound to the mitochondrial fraction of rat neural tissue (N E Sirett et al. 1977). Since 
then, AngII binding has been demonstrated in mitochondria from kidney and adrenal 
tissue (van Kats et al. 2001) whilst AngII and AT1R have been reported to co-localise 
on the outer mitochondrial membrane in rat vagal sensory cortex (Huang et al. 2003) 
and cerebellar cortex (Erdmann et al. 1996). 
Rather than cytosolic AngII operating at the outer mitochondrial membrane, there is 
also evidence to suggest that an intra-mitochondrial RAS might exist, capable of de-
novo AngII synthesis. Intra-mitochondrial ‘dense bodies’ isolated from the rat adrenal 
cortex were reported to contain renin, angiotensinogen and ACE (Peters et al. 1996; 
Rong et al. 1994) whilst renin co-localises with mitochondria on confocal microscopy of 
cardiomyoblasts (Wanka et al. 2009). The intramitochondrial presence of AngII 
precursors and necessary AngII forming enzymes would argue for the existence of an 
intramitochondrial RAS (mRAS). 
Any such mRAS could not be wholly mitochondrial since both renin and 
angiotensinogen are nuclear encoded proteins. Their presence within mitochondria 
must be dependent on either protein or RNA transfer across mitochondrial membranes. 
Both these processes are well recognised. Human mitochondria are able to import both 
mRNA (Ahmed & Fisher 2009) and transfer RNA (tRNA) (Rubio et al. 2008) into the 
matrix where they are translated by ribosomes associated with the inner mitochondrial 
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membrane (Liu & Spremulli 2000) and inserted into the inner membrane by the oxidase 
assembly machinery (Herrmann & Neupert 2003; Schmidt et al. 2010). In support of 
such mechanisms enabling the construction of an mRAS, a truncated renin mRNA 
transcript (exon-1A renin) lacking the secretory pathway signalling sequence has been 
identified in adrenal gland tissue which seems able to be transported across the 
mitochondrial membranes (Clausmeyer et al. 2000; Clausmeyer et al. 1999). 
However, it is not necessary to prove the existence of truncated mRNA isoforms of all 
necessary RAS proteins; not all mitochondrial proteins are translated within 
mitochondria. The vast majority of mitochondrial proteins are synthesised in the cytosol 
and imported into one of the four mitochondrial compartments; the outer membrane 
(Endo & Yamano 2010), intermembrane space (van der Laan et al. 2010), inner 
membrane (Herrmann & Neupert 2003) or mitochondrial matrix (Wagner et al. 2009). 
As a result, whilst the mitochondrial genome encodes only 13 proteins, upwards of 
1500 proteins have been identified in the human mitochondrial proteome (Lopez et al. 
2000). 
Taken together, these data suggest that a mitochondrial RAS may exist, with 
component proteins and enzymes variously imported intact or as mRNA precursors.  
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1.12. Hypothesis 
The introduction has described the evidence for the influence of the RAS on 
mitochondrial function and data supporting the existence of a mitochondrial RAS. 
However, these data are gathered from studies in a range of tissues with no work 
identifying a complete intramitochondrial system.  
I therefore propose the following hypothesis: 
H1: There is a local renin-angiotensin system in liver mitochondria. 
I sought to examine this hypothesis in liver since this is a tissue with a high 
mitochondrial content consisting of a single homogenous population. Other tissues 
such as muscle have multiple mitchondrial populations (in muscle; subsarcolemmal and 
intermyofibrillar) which are distinct in activity and function. Separating these populations 
is scientifically necessary, but reduces the yield considerably.  Organs such as kidney 
are smaller in size and contain more connective tissue, making homogenization 
difficult, again reducing the yield. Liver, being a large organ with little connective tissue 
and a high mitochondrial density, provides an aqaquate yield to support the 
experiments conducted in this work.  Further, a mitochondrial RAS is likely to be highly 
conserved in evolutionary terms given mitochondrial phylogeny; it is likely to be 
ubiquitous and as such should be present in liver tissue.  
Four complementary techniques were employed to ascertain whether RAS proteins 
exist within mitochondria and whether a functional effect of such a RAS could be 
identified. Proteomic surveys of both existing databases and isolated liver mitochondria 
were conducted, alongside attempted identification of AngII receptors by 
immunoprecipitation and Western blotting. Radioligand binding studies using labelled 
AngII were performed with mitochondrial and associated membranes and respirometric 
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studies with isolated crude mitochondria were run. Chapter 2 describes the methods 
used in all these experiments.  
In Chapter 3 I show that no RAS proteins could be identified in liver mitochondria by 
proteomic survey. In Chapter 4 I describe attempts to identify AngII receptors, which 
were ultimately unsuccessful. Chapter 5 goes on to show that AngII binds to MAM but 
not to pure mitochondria, and that the binding sites are likely AT1R. Finally, Chapter 6 
details the limited effect of AngII on the respiration of isolated mitochondria. 
1.13. Background data from within research group  
(Work conducted by Dr James Skipworth) 
1.13.1. Lack of detectable ACE in liver mitochondria 
If a fully functional intramitochondrial RAS exists in liver mitochondria, enzymes 
catalysing the final essential step of AngII synthesis from AngI should be present. As 
the most evolutionary conserved of all the RAS components, ACE is the most likely 
candidate to perform this function especially given its apparent presence in 
intramitochondrial dense bodies in the zona glomerulosa (Peters et al. 1996). The 
presence of ACE was thus sought in purified mitochondria from rat liver. An antibody 
directed to the C-terminus of the protein recognised a high molecular weight (MW) 
band at the predicted weight of ACE (MW ≈ 150 KDa) in the homogenate, nuclear, 
lysosomal and microsomal fractions but not in the mitochondria. However, a low MW 
band (≈ 50 kDa) band was enriched in the crude mitochondrial and pure mitochondrial 
fractions. 
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Figure 5. Western blot using anti-ACE and anit-grp-75 antibodies in rat liver subfractions. H-
homogenate, N-nuclear fraction, C-cytosol, L-lysosomes, Mc-microsomes. Rat liver mitochondria 
were purified by differential centrifugation (CM) and further separated into mitochondria associated 
membranes (MAM) and pure mitochondrial (PM) fractions by isopicnic Percoll centrifugation (for 
details see Methods 2.2). Mitochondrial fractions contain only a non-canonical 50kD 
immunoreactive band. 
 
Since a shorter isoform of human and rat ACE exists (ACE-T, Uniprot P47820) the 
identity of the lower MW band was sought by mass spectrometry of the 
immunoprecipitated protein. However, analysis of this band did not return any ACE 
related sequences, indicating non-specific binding by the antibody.  
Whilst these data appeared to exclude the possibility of intramitochondrial generation of 
AngII by ACE, they did not exclude AngII generation by other enzymes. Further, rather 
than being generated within the mitochondrial matrix, AngII may be imported into 
mitochondria or act upon the outer membrane.  
I conducted a series of experiments to investigate these possibilities. 
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2. METHODS 
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2.1. Mass Spectrometry 
2.1.1. Introduction 
Mass spectrometry is a powerful analytical tool used to measure the anatomical mass 
of a given sample. For biological samples such as peptides, it can measure to an 
accuracy of 0.01%, allowing for the differentiation of proteins according to amino acid 
substitutions or post translational modifications.  
Modern mass spectrometers consist of three main components; an ionisation source, 
an analyser and a detector. The principle of the technique depends on sample 
molecules being ionised, which then allows them to be separated according to their 
mass (m)-to-charge (z) ratios (m/z). Once separated, the detector produces a signal 
combining the m/z ratio value, the molecular mass and relative abundance or each ion 
(m/z spectrum).  
There are various methods for sample ionization, though the most frequently employed 
are Electrospray Ionisation (ESI) and Matrix Assisted Laser Desorption Ionisation 
(MALDI). In ESI, the sample is dissolved in a polar, volatile solvent which is then 
sprayed through a fine capillary tube to which a high voltage is applied. The emerging 
droplets become highly charged and as they evaporate produce individual charged 
sample ions free from solvent. In MALDI, sample molecules are bombarded with laser 
light to bring about ionisation. To avoid decomposition of the analyte by direct expose 
to laser energy, the sample is pre-mixed with a matrix compound which absorbs laser 
energy, transforming it into excitation energy for the sample. 
2.1.2. Peptide sequencing by Mass Spectrometry  
To sequence peptides by mass spectrometry, first the large peptide molecules must be 
broken into constituent fragments. For peptide sequencing, digestion of the sample 
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using sequence specific cleavage agents, such as trypsin, is most often employed. The 
digested mixture is analysed using ESI or MALDI without further separation in the first 
instance to generate a list of molecular masses. 
From this mix, individual peptides are selected to be analysed further by tandem mass 
spectrometric amino acid sequencing to generate sequence information. In this, 
selected sample ions are passed into a collision cell and bombarded by gas molecules 
(usually argon) to cause fragmentation. Fragmentation occurs at reasonably well 
documented points (Roepstorff & Fohlman 1984) with the number of fragments 
determined by the energy of the collider; time-of-flight colliders cause less 
fragmentation. These fragments are then analysed by a second analyser to provide m/z 
ratios (Phillips et al. 2012). 
The amount of sequence information varies from one peptide to another. Whilst some 
proteins provide enough information to cover 70-80% of a protein sequence, often a 
sequence of 4-5 amino acids from a single proteolytic peptide product is sufficient to 
identify a protein from a database.  
The mass spectrometry assays included in this thesis were performed by experienced 
technical staff in the Taplin Mass Spectrometry facility at Harvard Medical School (MA, 
USA) using a dual source (MALDI and ESI) time of flight mass spectrometer (Orbitrap 
mass spectrometers,Thermo Scientific, MA, USA). 
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2.2. Isolation of mitochondria and other subcellular fractions 
2.2.1. Isolation of subcellular fractions 
Livers from 12-week old male Sprague-Dawley rats were excised and placed in ice cold 
isolation medium A (see Appendix 1.1) before mincing and washing in the same 
medium, supplemented with a protease inhibitor cocktail. Livers were homogenised in a 
Potter-Elvehjem homogeniser, and the homogenate centrifuged at 800 g for 10 
minutes. Nuclear material formed the pellet with a post-nuclear supernatant. The 
supernatant was centrifuged at 10,300 g for 10 minutes resulting in the crude 
mitochondrial (CM) pellet and post-mitochondrial supernatant. This supernatant was 
then centrifuged at 25,000 g for 30 minutes producing a lysosomal pellet. All these 
steps were performed using a Beckman J2-MC Centrifuge with a JA-20 rotor. Finally, 
the post lysosomal supernatant was centrifuged at 100,000 g for 1 hour (Beckman 70 
ultracentrifuge with a 70.1 Ti rotor) to produce the microsomal pellet and a cytosolic 
supernatant. All pellets were resuspended in 500 µl of isolation medium A in a cryovial 
before snap freezing in liquid nitrogen and storing at -80 °C. All isolation steps, 
including centrifugation, were carried out at 4 °C. 
2.2.2. Isolation of pure mitochondria and mitochondria assocaited membranes  
Percoll density gradient separation was used to separate pure mitochondria (PM) from 
mitochondria assocaited membranes (MAM). Crude mitochondria were prepared as 
described above and then layered on a column of 30% (vol/vol) Percoll in isolation 
medium B (Appendix 1.1) before centrifuging at 95,000 g for 40 minutes (Beckman L-
70 Ultra-Centrifuge with an SW41 rotor). The two bands (upper band; MAM, lower 
band; PM, see Fig 6C) were aspirated and diluted in 500 µl of isolation medium A 
before being centrifuged at 6300 g for 10 minutes (Beckman J2-MC Centrifuge; JA20.1 
rotor). The pellet of the PM fraction was resuspended in 500 µl of isolation medium A in 
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a cryovial and snap frozen in liquid nitrogen. The supernatant from the MAM fraction 
was then subjected to centrifugation at 100,000 g for 1 hour (Beckman L-70 Ultra-
Centrifuge with 70.1 Ti rotor) to pellet the purified MAM. The pellet was resuspended in 
500 µl of isolation medium A (without protease inhibitor) in a cryovial, snap frozen in 
liquid nitrogen and stored at -80 °C.  
2.2.3. Determination of mitochondrial protein topology 
Proteinase K digestion was used to differentiate proteins integral to the mitochondrial 
outer membrane from those residing in the inner membrane and matrix. When isolated 
mitochondria are exposed to Proteinase K, proteins expressed on the outer membrane 
will be cleaved but the outer membrane remains intact, protecting inner membrane 
proteins from digestion. Sodium carbonate extraction can then be performed, lysing 
mitochondria and thus freeing matrix proteins. The inner membrane can then be 
isolated and the matrix proteins precipitated. 
Proteinase K was added to 50 µg of PM to a final concentration of 50 µg/ml and 
incubated on ice for 10 minutes. Phenylmethanesulfonyl fluoride (PMSF) was then 
added to a final concentration of 1 mM to inhibit Proteinase K. Following a further 10 
minute incubation on ice the mitochondria were pelleted by centrifugation at 10,000 g 
for 10 minutes (Beckman J2-MC Centrifuge with a JA-20 rotor), resuspended in 50 µl 
isolation medium A and a sample (PK) snap frozen in liquid nitrogen and stored at -80 
°C. 
To lyse mitochondria, 50 µg of proteinase K digested PM were resuspended in 100 µl 
sodium carbonate solution and incubated on ice for 30 minutes. Mitochondrial 
membranes were pelleted by centrifugation at 100,000g for 30 minutes (Beckman L-70 
Ultra-Centrifuge with 70.1 Ti rotor). The soluble proteins in the supernatant were then 
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precipitated using 72 % Trichloroacetic acid (TCA). This sample represents the matrix 
proteins (MX). 
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Figure 6. Protocol for isolation of subcellular fractions and mitochondrial membranes. (A) 
Sequential centrifugation to isolate subcellular fractions. (B) Ultracentrifugation protocol for crude 
mitochondrial separation. (C) Photograph of centrifuge tube following ultracentrifugation of crude 
mitochondrial fraction. MAM comprise the top band and pure mitochondria (PM) the lower band.  
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2.2.4. TCA precipitation of proteins 
Protein samples were diluted with 72 % TCA to make a final 12 % TCA concentration 
and incubated on ice for 30 minutes. Samples were then centrifuged at 18,000 g for 30 
minutes at 4 °C. The pellet was washed in 200 µl of acetone and centrifuged at 10,000 
g for 10 minutes. This acetone wash was repeated twice. The resulting washed pellet 
was allowed to dry at 95 °C for 10 minutes and then resuspended in 50 µl isolation 
medium A, snap frozen in liquid nitrogen and stored at -80 °C. 
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2.2.5. Protein quantification 
The protein concentration of a given sample was determined using bicinchoninic acid 
(BCA) protein assay reagent kit (Pierce, Rockford, IL, USA) according to the 
manufacturer’s instructions. This method utilises the reducing property of proteins in an 
alkaline solution to reduce Cu2+ to Cu1+. The chelation of two molecules of BCA with 
one Cu1+ produces a purple colouration of the solution, which exhibits a strong linear 
absorbance at 562 nm as concentration increases. The absorbance of a sample can 
then be compared to that of a known set of standards (diluted over the working range of 
20 – 2000 µl/mL). 
Samples were lysed by mixing 1:1 with non-BSA containing lysis buffer (see Appendix 
1.3) and incubating for 10 minutes. DNA was pelleted by centrifugation at 16,100 g for 
10 minutes and the supernatant removed for quantification. Each sample was assayed 
in duplicate on a 96 well plate with 5 µl of protein sample added to each well. A series 
of known protein concentrations was prepared from an albumin standard (2 mg/mL) 
and 5 µl of each added to wells of the plate in duplicate. 195 µl of BCA reagent was 
added to each well and the plate then incubated at 37 °C for 30 minutes. Absorbance 
was measured at 562 nm using a spectrophotometer. The absorbance of the blank 
standard was subtracted from all other measurements. A standard curve was 
generated from the absorbance of the known standards and a trend line fitted. The 
protein concentration of the samples was calculated according to the equation of the 
trend line. 
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2.3. Western blotting  
2.3.1. Introduction 
Western blotting is used to detect specific proteins by way of separation according to 
size. Gel electrophoresis can separate native proteins based on their 3D structure or 
denatured proteins by the length of the polypeptide. The gels are usually 
polyacrylamide (made from acrylamide and N,N-methylenebisacrylamide (Bis)) and are 
neural, hydrophilic, 3D networks of long hydrocarbons cross-linked by methylene 
groups. The size of the pores in this 3D matrix is determined by the relative amount of 
Bis and acrylamide, giving the gels a % w/v property. Sodium dodecyl sulfate (SDS) 
added to protein samples gives each protein a negative charge proportional to its mass. 
Passing a voltage through the gel causes the negatively charged proteins to migrate 
away from the anode according to their charge and therefore mass.  
Once proteins are separated within the gel, they can be induced to transfer onto a 
membrane by application of an electric field. The gel is stacked on top of a membrane, 
and filter paper placed either side. The stack is placed with the membrane closest to 
the positive electrode so that the negatively charged proteins migrate from gel to 
membrane. 
2.3.2. Protocol 
Samples were diluted 1:4 with Laemmli buffer (Appendix 1.3) and incubated in boiling 
water for 10 minutes to denature proteins. Proteins were resolved using 4-12% Bis-Tris 
glycine pre-cast gels (Invitrogen, Paisley, Uk). Samples were prepared with 5 x SDS 
buffer (1:5) before heating in boiling water for 10 mins. Equal amounts of protein were 
loaded into wells alongside a molecular marker cocktail. Gels were run at 100 V in 1 x 
SDS running buffer (Appendix 1.3). Once the dye had migrated through the gel, 
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proteins were transferred from the gel to nitrocellulose or polyvinylidene diflouride 
(PVDF) membranes using a semi-dry transblot electro-transfer system (Bio-Rad, CA, 
USA). Membranes were activated in 100% methanol for 1 minute before being wetted 
in transfer buffer (Appendix 1.3), layered beneath the gel and run for 1 hour at 20 V. 
Once the transfer was complete membranes were blocked for 1 hour with 5% bovine 
serum albumin (BSA) diluted in phosphate-buffered saline with Tween-20 (PBST) 
(Appendix 1.3) or alternatively PBST with 5% fat-free milk. Membranes were then 
washed 3 times in PBST before incubation with primary antibody.  
Following primary incubation, membranes were washed three times for 5 minutes in 
PBST before incubation with horseradish peroxidase (HRP)-conjugated secondary 
antibodies (Appendix 1.3). Membranes were developed with the enhanced 
chemiluminescence detection kit (Pierce, Rockford, IL, USA). 
2.3.3. Coomassie staining 
Proteins were visualised in the gel by treating them with a solution of 7 % acetic acid, 
40 % ethanol and 0.1 % Coomassie Brilliant Blue (Life Sciences, UK). Proteins are 
visualised as blue bands on a clear background. Following imaging, excess stain was 
removed by multiple washes in a solution containing 0.7 % acetic acid and 20 % 
ethanol. 
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2.4. Validation of mitochondrial membrane isolation 
In order to validate the mitochondrial isolation protocol, Western blots were performed 
with all cell subfractions. Membranes were probed with antibody to CoxIV (#4844, Cell 
Signalling, MA, USA), an integral inner mitochondrial membrane protein of 17 KDa.  
 
Figure 7. Cox IV immunostaining of subcellular fractions. Following the protocol of differential 
centrifugation, nuclear (N) microsomal (Mc), Lysosomal (L), cytosolic (Cyt) and crude mitochondrial 
(CM) fractions were isolated. Percoll density ultracentrifugation of the CM fraction separated pure 
mitochondria (PM) from mitochondrial-associated membranes (MAM). Proteinase K was used to 
digest outer membrane proteins (PK) before a sodium carbonate extraction of the PK fraction 
separated inner mitochondrial membranes (IMM) and mitochondrial matrix (Mx) proteins. Each lane 
of a Bis-Tris 4-12% agarose gel was loaded with 40 µg of protein. Proteins were transferred onto a 
PVDF membrane before incubation with primary antibody for 16hrs at 4 ˚C followed by application 
of a horseradish peroxidase conjugated secondary antibody for 2 hours. Cox IV immunoblotting 
revealed distinct bands in H, N, CM PM, PK and IMM, with faint bands in MAM, Mc, L and Cyt. 
The results with CoxIV immunoblotting suggest that the isolation technique successfully 
enriches mitochondria in the pure mitochondrial fraction. The pattern of increasingly 
intense bands in the crude and pure mitochondrial fractions is in keeping with an 
integral mitochondrial protein. The lack of change in intensity following Proteinase K 
digestion is consistent with the inner mitochondrial membrane location of CoxIV, as well 
as suggesting maintained inner mitochondrial membrane integrity. Faint bands in other 
fractions suggest minor mitochondrial contamination. 
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2.5. Immunoprecipitation 
2.5.1. Introduction 
Immunoprecipitation refers to the process of antigen affinity purification utilising a 
specific antibody. When incubated with the antigen-containing solution, antibody and 
antigen will form a complex. By immobilising the specific antibody by attachment to an 
insoluble support of high molecular weight (such as an agarose bead) the complex it 
forms with the specific antigen can be separated from a complex solution (such as cell 
lysate) by centrifugation.  
Protein A, Protein G and Protein A/G are the most commonly employed 
immunoglobulin-binding proteins and each shows specificity for the heavy chains on 
the Fc region of antibodies. When immobilised on an agarose bead they are effective 
tools for attaching antibody. 
Since the antibody binding affinity of Protein A/G is non-specific (and will thus bind any 
other antibody in solution), a pre-clearing step is usually employed to clear the solution 
of non-specific antibody. Protein A/G is incubated with sample solution and then 
subjected to centrifugation; the pelleted Protein A/G will be bound to non-specific 
antibodies. The supernatant can then be used as the input for the immunoprecipitation 
step with the specific antibody of choice.  
2.5.2. Protocol 
Samples were solubilised using immunoprecipitation buffer (containing Triton X-100, 
protease inhibitor and phosphatase inhibitor) and lysates were centrifuged at 14,000 
rpm for 30 minutes. The supernatants (400 μg of total protein) were first pre-cleared 
with equilibrated Protein A/G sepharose beads (GE Healthcare, Buckinghamshire, UK). 
Twenty µl of Protein A/G was added to 400 µg of sample proteins and rotated in tubes 
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for 1 hour. Following centrifugation, the supernatant (input) was incubated overnight 
with Protein A/G and 2 µg of primary antibody (Sc-1173; anti AT1R, or sc 9140; anti-
AT2R, both Santa Cruz, CA, USA). Further centrifugation separated the antigen bound 
bead complex (pellet) from the output (supernatant). The pellet was resuspended in 
sample buffer before heating at 95 °C to separate antigen from antibody-Protein A/G 
complex. After a further centrifugation, the antigen of interest along with antibody 
devoid of agarose bead- protein A/G complex (elute) forms the supernatant. 
Immunoprecipitated proteins were resolved using NuPAGE Bis-Tris gels (Invitrogen, 
Paisley, UK) as described previously.  
 
Figure 8. Schematic of immunoprecipitation using Protein A/G and agarose beads. 
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2.6. Cell culture and small interfering RNA inoculation 
2.6.1. HepG2 cell culture 
HepG2 cells are a perpetual human cell line derived from a well-differentiated 
hepatocellular carcinoma in a Caucasian male. They are epithelial in morphology and 
display a high degree of functional differentiation in vitro making them a suitable model 
for studies of liver metabolism. HepG2 cells were cultured in 75 cm2 flasks in 
Dulbecco’s Modified Eagle’s Medium (DMEM; Invitrogen, Carlbad, CA, USA) 
supplemented with foetal bovine serum and streptomycin. Flasks were incubated at 
37˚C in 5% CO2 atmosphere.  
2.6.2. Small interfering RNA inoculation  
HepG2 cells were cultured in 6 well plates (at approximately 250,000 seeded cells/well 
on day 0). On day 1 (at approximately 60% confluency), cells were transfected with the 
chosen small interfering RNA (siRNA). Two vials were prepared; first 10 µl of siRNA 
was added to 190 µl DMEM, secondly 6 µl DharmaFECT 4 (GE Healthcare, 
Amersham, Herts, UK) was added to 194 µl DMEM. After 5 minutes, the vials were 
mixed and left at room temperature for 20 minutes. The media in the 6 well plates was 
removed and 1.6 ml DMEM added. The siRNA mix was then added and the cells 
incubated for 48hours at 37 ˚C in 5% CO2 atmosphere. Harvesting of cells was 
achieved with 0.25% Trypsin (#T4049 Sigma Aldrich, Dorset, UK) and centrifugation 
(3000 rpm, 4 minutes). Pelleted cells were stored at -80 ˚C. Cell lysates were prepared 
using non-BSA containing lysis buffer, supplemented with protease and phosphatase 
inhibitors. 
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2.7. Radioligand binding 
2.7.1. Introduction 
Ligand binding assays can measure both the affinity of ligands for a given receptor and 
also the density of that receptor in a membrane preparation. Three variables are of 
particular interest; the equilibrium dissociation constant (KD), the maximum density of 
receptors (BMAX) and the Hill coefficient (nH). The KD denotes the concentration of 
ligand that will occupy 50% of the receptors and as such is a measure of strength of 
ligand-receptor interaction. BMAX. is measured in amount of ligand/mg protein assayed. 
Saturation binding assays can be used to determine both these variables. The Hill 
coefficient describes the binding cooperativity of a receptor site.  
2.7.1.1. Saturation binding 
Saturation binding refers to a technique in which membranes are exposed to 
radiolabelled ligand in optimal binding conditions and the amount of bound ligand at 
equilibrium quantified. This is achieved by incubating membrane preparations with 
radiolabelled ligand for a pre-determined time (and temperature) to reach equilibrium, 
which is then broken by centrifugation. Unbound ligand can be removed from bound 
ligand by resuspension in Tris-HCl and re-centrifugation. Unbound ligand will be 
retained in the supernatant, whilst bound labelled ligand can be measured by Geiger 
counter. However, binding of ligand will include both binding to specific binding sites 
and non-specific binding.  
Non-specific binding can be quantified by running experiments in parallel in which 
membrane preparations are incubated with radiolabelled ligand and 1000 fold excess of 
unlabelled ligand. The excess unlabelled ligand will compete successfully for specific 
binding sites leaving radioligand to bind non-specific sites only. Once quantified (as 
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before) this value for non-specific binding can be subtracted from the total binding value 
to give specific binding. Plots of these binding values can give an approximation of BMAX 
(the amount of specific binding observed where the isotherm plateaus) and the KD (the 
ligand concentration at 50% of BMAX) (Fig. 9). The shape of these curves roughly 
describes the Hill slope. A value of 1.0 denotes a ligand binding to a single site with no 
cooperativity (that is, binding of ligand does not increase the affinity of the receptor to 
bind further ligand). A value greater than 1.0 suggests more than one binding site with 
positive cooperativity; less than 1.0 suggests multiple binding sites with varying affinity 
or negative cooperativity. More accurate estimates can be made from linearising the 
data in a Scatchard plot. More commonly, complex line fitting programmes are 
employed. In the work presented, data were analysed using the iterative non-linear 
curve fitting programmes Kinetic and LIGAND (KELL package, Elsevier Biosoft, 
Cambridge, UK). 
 
Figure 9. Graphical representation of a ligand-binding saturation assay. Total binding is measured 
with radiolabelled ligand alone, giving a saturation curve (in red). Non-specific binding is measured 
with radiolabelled ligand in the presence of 1000 fold excess unlabelled ligand. Labelled ligand will 
bind non-specific sites in a linear fashion (blue line). Specific binding can then be calculated by 
deducting non-specific from total binding values.  
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2.7.1.2. Competition binding 
With the KD defined for a given ligand in saturation assays, the ability of other ligands to 
displace this specific binding can be measured. Competition curves are obtained by 
plotting specific binding in the presence of competitors as a percentage of total binding, 
against the concentration of the competing ligand. With reference to AngII receptors, 
the specific inhibitors of AT1R (losartan) and AT2R (PD123319) were used to assess 
receptor type. 
2.7.2. Protocol 
2.7.2.1. Saturation binding 
Mitochondrial homogenates (100 µL) were incubated in assay buffer (Appendix 1.4) 
with increasing concentrations (15 pM-2 nM) of [125I]-AngII (in a final volume of 200 µL) 
for 1 hour at room temperature (22 ˚C). Unlabeled AngII (10 µM) was used to determine 
non-specific binding at each concentration in duplicate tubes. Homogenates were 
centrifuged (20,000 g, 10min, 4 ˚C) to break equilibrium, pellets re-suspended in 500 µL 
ice-cold Tris-HCL (50 mM, pH 7.4) to remove unbound ligand and centrifuged as 
previously. Resulting pellets were counted in a gamma counter. Data from these 
experiments were analysed using the iterative non-linear curve fitting programs Kinetic 
and Ligand (KELL package, Elsevier Biosoft, Cambridge, U.K.) to determine KD, BMAX 
and nH. 
2.7.2.2. Fixed concentration competition assays 
Homogenates (100 µL) were incubated in assay buffer as previously with 0.5 nM [125I]-
AngII (in a final volume of 200 µL) for 1 hour at room temperature (22 ˚C), with or 
without the addition of AngII (10 µM) to determine non-specific binding. Additionally, 
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either the AT1R specific antagonist losartan (1 µM) or the specific AT2R antagonist 
PD123319 (1 µM) were included to determine presence of AT1R vs. AT2R. 
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2.8. Respirometry  
2.8.1. Introduction 
Since the reduction of O2 at complex IV is a crucial step in OXPHOS, measuring 
oxygen consumption of tissues, cells or isolated mitochondria has been a cornerstone 
in investigations of mitochondrial (dys)function since it was first developed by Chance 
and Williams in the 1950s. Since then, various apparatus have been used in the pursuit 
of increasingly accurate measurements of mitochondrial oxygen consumption. 
However, the function of the majority of such apparatus is based on the same principals 
governing the early Clark electrodes. 
The Clark-type polarographic oxygen sensor consists of a gold cathode, a silver/silver 
chloride anode and a potassium chloride electrolyte reservoir. The sensor is separated 
from a sample suspended in solution within a chamber by a 25 µM membrane, across 
which a fixed voltage is applied (usually 0.8 V). Oxygen diffuses from the sample 
solution to the cathode surface across the membrane and then the electrolyte layer. As 
oxygen diffuses across the membrane it is reduced by the fixed voltage which then 
generates a current. Since the oxygen tension is held at close to zero at the cathode, 
under steady-state conditions the oxygen flux to the cathode depends on the external 
oxygen pressure and is therefore in proportion to the concentration of oxygen in the 
solution. 
The raw signal is converted to oxygen concentration (µM or nmol.ml-1) by calibration of 
the oxygen sensor against two-points; usually achieved at air saturation and zero 
oxygen concentration. The measured oxygen flow can then be converted to an oxygen 
flux per sample size (e.g. mass of mitochondrial protein).  
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Various factors can affect the sensitivity of a Clark electrode. In a 2 ml volume of liquid, 
oxygen concentration will vary according to distance from the air/surface interface. This 
can result in the membrane being exposed to an unrepresentative sample of fluid. To 
minimize this, a stirrer is used to effectively mix the sample throughout the course of 
the experiment. The permeability of the membrane will also affect the signal at the 
oxygen sensors and for this reason it must be kept at constant temperature. Residual 
oxygen diffusion from stir bars, stoppers and from the chamber materials themselves 
can all affect flux readings.  
The Oxygraph 2K (Oroboros Instruments, Innsbruck, Austria) is a high resolution 
system which combines precise temperature control with a system built with inert 
materials and sensitive membranes resulting in a residual oxygen consumption of less 
than 2 pmol.s-1.ml-1 and a detection limit of 0.5 pmol.s-1.ml-1, allowing accurate 
measurement of oxygen flux in small amounts of tissue. Whilst measurements can be 
made in whole cells, the permeability of the cell membrane means that some 
mitochondrial modulators are not effective. A more detailed analysis of mitochondrial 
pathways can be made with isolated mitochondria.  
2.8.2. Mitochondrial isolation for respirometry 
Liver mitochondria were isolated immediately after tissue harvesting at 4oC. The 
excised livers were immersed in ice-cold isolation medium A (Appendix 1.1) and 
minced with scissors followed by homogenisation by Potter-Elvehjem homogeniser. 
The homogenate was centrifuged for 10 minutes at 700 g. The supernatant was 
collected and centrifuged three times for 10 minutes at 7,000 g. Pellets (CM) were re-
suspended in isolation medium A to a final concentration of 50-100 mg protein ml-1. 
Protein concentration was measured using the Pierce BCA Protein Assay kit (Thermo 
scientific, MA, USA) according to manufacturer instructions. 
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2.8.3. Experimental conditions 
All experiments were conducted at 37 ˚C to replicate in vivo conditions. However, 
oxygen concentrations over the course of the experiment are non-physiological. In vivo, 
oxygen partial pressure (ƿO2) decreases as it cascades from the atmosphere (20 kPa) 
to alveolar (13 kPa), mixed capillary (3 kPa) and sarcoplasmic (0.3-0.5 kPa) 
environments. This intracellular ƿO2 equates to roughly 3 µM or 3 nmol ml
-1 (Gnaiger et 
al. 1998). However, by virtue of the design of oxygen consumption experiments, the 
starting ƿO2 needs to be greater than this in order for O2 availability not to be rate 
limiting during the course of the experiment. Conversely, exposing isolated 
mitochondria to supra-physiological ƿO2 may induce oxidative stress through excess 
ROS production or be directly toxic. This dilemma is well recognised in the field of 
mitochondrial respirometry. As a practical compromise, experimental oxygen 
concentrations were maintained in the range 200 - 50 nmol/L (200 - 50 µM) ensuring 
that respiration was not restricted by O2 availability. Additionally, since all experiments 
were run with contemporary control assays, all mitochondrial samples were exposed to 
the same conditions. 
2.8.4. Measurement of mitochondrial respiration 
Using the Clark electrode, various aspects of mitochondrial respiration can be 
interrogated. State 2, State 3 and State 4 respiration can all be measured by using a 
chosen substrate and measuring respiration rates before addition of ADP (State 2), 
respiration on ADP (State 3) and respiration following consumption of ADP (State 4). 
However, this measure of State 4 is susceptible to inaccuracies caused by 
contamination of the sample with ATPase (recycling ADP). A more accurate measure 
of State 4 respiration can be achieved by using an ‘uncoupler’ of the ETS such as 
oligomycin (which is an inhibitor of ATP synthase). This effectively inhibits complex IV 
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and thus gives an accurate measure of non-ETS coupled or LEAK respiration, termed 
State 4oligo. 
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Figure 10. Representative trace of respirometry assay using Hansatech oxygraph. Mitochondria 
were suspended in respiration medium (Appendix 1.5) with pyruvate (5 mM) and malate (5 mM) and 
allowed to respire for 5 minutes in the absence of exogenous ADP. ADP was added in a 
submaximal dose to allow for State 4 measurement. State 3 was measured in the presence of a 
saturating concentration of ADP. LEAK respiration was assessed after adding oligomycin. 
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2.8.4.1. Individual Complex activities 
The activity of individual complexes of the ETS can be assessed by using substrates 
specific to that complex in the presence/absence of inhibitors of other complexes (Fig. 
11). Glutamate and pyruvate, in the presence of malate (but not malate on its own) 
support complex I respiration by providing NADH via the TCA cycle. Complex II activity 
can be isolated by applying the complex I specific inhibitor rotenone and the addition of 
succinate (the substrate for the succinate dehydrogenase subunit of complex II). 
Similarly, complex IV activity can be isolated by providing its (artificial) substrates 
N,N,N′,N′-tetramethyl-p-phenylenediamine (TMPD) and ascorbate, in the presence of 
antimycin A (a specific inhibitor of complex III). Due to active auto-oxidation of reduced 
TMPD in the chamber, sodium azide is often added to terminate State 3 respiration at 
complex IV. In this way, pathology relating to individual complexes can be identified. 
 
Figure 11. Substrate-inhibitor titration for respirometry in isolated mitochondria. Glutamate, 
pyruvate and malate support complex I respiration. Addition of rotenone inhibits complex I allowing 
complex II respiration to be assessed with addition of its substrate, succinate. Complex IV 
respiration is stimulated by addition of ascorbate and TMPD having inhibited complex III with 
antimycin A. Q; Coenzyme Q, C; Cytochrome C. 
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Figure 12. Representative traces of mitochondrial respiration form Oxygraph-2K. Isolated 
mitochondria were resuspended in respiration medium (Appendix 1.5) at a concentration of 0.4 
mg/ml. Respiration rates were measured at 37ºC. (A) Complex I-dependent respiration was 
measured with glutamate (10 mM) plus malate (5 mM), followed by addition of ADP (0.5 mM). (B) 
Complex II-dependent respiration; first complex I was inhibited with rotenone (0.5 μM), and then 
succinate (10 mM) was added, followed by addition of ADP (0.5 mM). (C) Complex IV-dependent 
respiration was measured by adding ascorbate (4 mM) and TMPD (0.5 mM) followed by ADP (0.5 
mM). Since TMPD exhibited a wide range of auto-oxidation in the buffer, respiration was finally 
inhibited with sodium azide (5 mM), and the difference between the oxygen consumption before 
and after the addition of sodium azide was interpreted as the real complex IV (State 3) respiration. 
The coupling of phosphorylation to oxidation was determined by calculating the respiratory control 
ratio (RCR) as the ratio between ADP-stimulated respiration (State 3) and respiration after ADP 
depletion (State 4). 
2.8.4.2. ADP/O ratio 
The ‘P/O ratio’ classically refers to the amount of ATP produced per oxygen atom 
reduced by the respiratory chain (ATP/O ratio). When using an oxygen electrode the 
amount of oxygen consumed on addition of a known amount of ADP (ADP/O ratio) can 
be used as a surrogate. It is a measure of the stoichiometry of the ATPase and that of 
O2 reduction at complex IV and is therefore a constant for a given substrate (Hinkle 
2005). It is therefore useful in assessing the ‘health’ of a mitochondrial isolate, but not 
in identifying (dys)function. 
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2.8.4.3. Respiratory acceptor control ratio (RCR) 
The RCR is defined as the respiration rate in State 3 divided by that in State 4 (State 
3/State 4). Healthy mitochondria display high respiratory control; they have the ability to 
markedly increase their rate of respiration in the presence of ADP to achieve high ATP 
output followed by a return to a resting low rate of respiration. A high RCR suggests 
that the mitochondria have high oxidative capacity with low proton leak. However, 
mitochondria from different tissues have different RCRs whilst the RCR for a given 
mitochondrion will vary depending on the substrate on which it respires. Importantly, 
any change in mitochondrial oxidative phosphorylating ability will be reflected in an 
altered RCR, making it a sensitive marker of mitochondrial (dys)function. If absolute 
rates of respiration and RCR are unaffected by an experimental condition it is unlikely 
that any bioenergetic dysfunction exists. 
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2.8.5. Isolation of functionally intact mitochondria 
To prove that the isolation of crude mitochondria provided functionally intact organelles, 
respiration states of isolated rat liver mitochondria were measured (Fig. 13). 
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Figure 13. Respiratory rates of isolated rat liver mitochondria. Mitochondria were suspended in 
respiration medium (Appendix 1.5) with pyruvate and malate. State 3 respiration was measured in 
the presence of a saturating concentration of ADP. State 4 respiration was measured following the 
consumption of ADP. LEAK respiration was assessed after adding oligomycin (State 4oligo). Data 
summarised from 3 runs in 3 different liver preparations (n=3). Data represent mean ± SEM. 
Differences were assessed with paired sample t tests.  
 
 Basal State 3 State 4 State 4oligo RCRoligo ADP/O 
Mean 410.7 2164.5 495.2 289.0 7.7 3.1 
SEM 29.4 101.4 20.2 4.7 0.4 0.4 
 
Table 1 Respiratory rates in isolated rat liver mitochondria. Respiratory control ratio (RCR) was 
calculated using State 4 induced with oligomycin. 
These data show that mitochondria isolated using the protocol described were 
functional and healthy. State 4 respiration rate was significantly higher than State4oligo, 
suggesting extra-mitochondrial ADP regeneration likely due to presence of ATPases 
(Hütter et al. 2006). Taking State4oligo as the better indicator of true State 4, respiration 
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rates (State 3 and State 4) and RCRoligo are within the expected ranges for 
mitochondria from 12-week old rat livers respiring on NADH linked substrates 
(Petrosillo et al. 2007; Long et al. 2006; Aprille & Asimakis 1980; Gold et al. 1968; 
Horton & Spencer 1981).  
The ADP/O ratio is also within the range of published data though at the higher end of 
reported values for NADH-linked substrates in liver mitochondria (Hinkle 2005). This is 
likely to be due to a combination of factors. The lack of Mg2+ in the respiration medium 
may have contributed since this has been shown to slow the transition from State 3 to 
State 4 making estimation of the State 3 end point difficult (Hinkle & Yu 1979). This is 
owing to the fact that ATP is a competitive inhibitor of ADP transport whilst Mg-ATP is 
not (Pfaff & Klingenberg 1968). The use of a Teflon bar may have caused 
underestimation of O2 consumption since it has been shown that Teflon adsorbs O2 and 
releases it slowly during experiments with Clark electrodes (Hinkle et al. 1991). Finally 
there is disagreement in the literature regarding wither basal O2 consumption should be 
deducted from calculations of ADP/O (Hinkle 2005). 
Overall, however, these data describe functional and healthy mitochondria, with good 
reproducibility of respiration rate between assays, as evident in the small SEMs.  
  
76 
 
2.9. Statistical analyses  
Data generated in the ligand binding studies and respirometry studies were subjected 
to statistical analyses.  
Ligand binding data were analysed using the iterative non-linear curve fitting 
programmes Kinetic and LIGAND (KELL package, Elsevier Biosoft, Cambridge, UK). 
Parametric variables were reported as Mean (SD). Statistical significance (95% 
confidence interval) was reported for p < 0.05. 
Statisistical analysis of respirometry data was performed using statistical software 
(Prism 5. Graphpad, CA. USA). Measures of central tendency for continuous variables 
were compared using Students’ T test (parametric variables) following normality testing. 
For data comprising multiple groups, one-way analysis of variance (ANOVA) was used 
with Dunnett’s test used for post hoc analysis. Parametric variables were reported as 
Mean (SEM). Statistical significance (95% confidence interval) was reported for p < 
0.05. 
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3. RESULTS: ANALYSIS 
OF THE 
MITOCHONDRIAL 
PROTEOME 
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3.1. Analysis of the mitochondrial proteome by mass spectrometry 
3.1.1. Western blotting crude mitochondrial fractions 
In searching for components of the RAS within mitochondria, a proteomic survey of 
mitochondrial fractions isolated from rat liver was carried out using mass spectrometry. 
Crude mitochondria (CM) were isolated from a single rat liver and then separated into 
pure mitochondrial (PM) and mitochondrial associated membrane (MAM) fractions (as 
described in Methods, chapter 2.2). These whole fractions were run on a 10% Bis-Tris 
gel by SDS-PAGE.  
 
Figure 14. Coomassie Brilliant Blue stain of mitochondrial fractions run on SDS-PAGE. Each well 
was loaded with 40 µg protein and run on a 10% Bis-Tris gel. CM; crude mitochondria, PM; pure 
mitochondria, MAM; mitochondria associated membranes.  
The gel was cut into sections in preparation for mass spectrometry (Figure 15). 
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Figure 15. Coomassie Brilliant Blue stained acrylamide gel showing sectioning of lanes in 
preparation for mass spectrometry. Each lane was loaded with 40 µg protein and run on a 10% Bis-
Tris gel. Lanes were cut into 4 or 5 sections and sent to the mass spectrometry facility for analysis. 
CM; crude mitochondria, PM; pure mitochondria, MAM; mitochondria associated membranes. 
Sections were cut from the 2D gel and sent to the Taplin mass spectrometry facility at 
Harvard Medical School (MA, USA). There, a dual source (MALDI and ESI) time of 
flight mass spectrometer (Orbitrap mass spectrometers, Thermo Scientific, MA, USA) 
was employed to identify peptides within the gel bands. Identified peptide sequences 
were cross matched with a protein database to provide protein matches. Any protein 
with three of more unique peptide matches was considered confidently identified in the 
sample. The Taplin Institute provided a list of all proteins that had any peptide 
sequence match, together with details of how many unique matches were found.  
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3.1.2. Results of mass spectrometry 
Analysis of the 2-D gel sections returned hundreds of protein matches in each 
mitochondrial fraction (CM fraction contained 754 proteins; PM: 464 proteins; MAM: 
713 proteins). To search for RAS components within this mitochondrial proteome, a list 
of all RAS related gene sets and their corresponding products was prepared using the 
AmiGO database (an online directory found at http://amigo.geneontology.org/amigo) 
which provides gene ontology details across species (see Appendix 2). The RAS 
related gene search encompassed biological processes and molecular functions. The 
proteins identified by mass spectrometry were cross referenced with the AmiGO gene 
list. To enable cross reference, proteins identified by mass spectrometry and proteins 
listed in the AmiGO gene set were given a common annotation as listed on the UniProt 
online directory (found at http://www.uniprot.org/). Intersections are listed in the 
following tables. 
Crude mitochondria 
UniProt term Entry term Protein name 
P50123 AMPE_RAT Aminopeptidase A  
P54311 GBB1_RAT Guanine nucleotide-binding protein 
subunit beta-1 
P00787 CATB_RAT Cathepsin B  
P00786 CATH_RAT Pro-cathepsin H  
Table 2. RAS related protein intersections with crude mitochondrial proteome identified by mass 
spectrometry. 
MAM 
UniProt term Entry term Protein name 
P50123 AMPE_RAT Aminopeptidase A 
Table 3. RAS related protein intersections with mitochondrial associated membrane (MAM) 
proteome identified by mass spectrometry. 
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Pure mitochondria 
UniProt term Entry term Protein name 
P50123 AMPE_RAT Aminopeptidase A 
Q68FT8 Q68FT8_RAT Protein Serpinf2; Serine peptidase 
inhibitor  
P00787 CATB_RAT Cathepsin B  
P00786 CATH_RAT Pro-cathepsin H  
P42676 NEUL_RAT Neurolysin, mitochondrial  
Table 4. RAS related protein intersections with pure mitochondrial proteome identified by mass 
spectrometry. 
Only five RAS related protein matches were identified in the pure mitochondrial fraction, 
none of which are RAS specific. The least closely related is protein Serpinf2, a serine 
protease inhibitor and a negative regulator of endopeptidase activity that seems to be 
involved in RAS signalling pathways in smooth muscle, leading to contraction. 
However, it does not have any direct interaction with RAS effector peptides or 
receptors. 
Cathepsin B is a cysteine endopeptidase with specificity for peptide bonds. It has been 
shown to catalyse the conversion of AngI to AngII in brain tissue (Azaryan et al. 1985) 
and is suggested to be involved in the intracellular processing of prorenin in cardiac 
tissue (Almeida et al. 2000). As such, it can perform the function of ACE whilst 
potentially also modulating renin availability. Cathepsin H is another member of the 
same class, and therefore capable of catalyzing similar reactions, though not 
documented to do so in the literature.  
Aminopeptidase A is a recognized angiotensinase. It is a membrane bound 
metalloprotease responsible for hydrolyzing the NH2 terminal aspartate of AngII to form 
AngIII (Erdös & Skidgel 1990; Zini et al. 1996). Initially identified in brain, it has since 
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been identified in other tissues including liver (Troyanovskaya et al. 1996; Gao et al. 
2014; Lojda & Gossrau 1980). Whilst AngIII is metabolically active, its recognised 
effects are mediated through action at the AT1R and AT2R (Swindle et al. 2013; 
Yugandhar & Clark 2013; Clark et al. 2012; Kandalam et al. 2014), neither of which was 
identified in the pure mitochondrial or other fractions.  
Neurolysin was also identified as a RAS related protein in the pure mitochondrial 
fraction. It is an oligopeptidase which was first identified in rat brain membrane as a 
novel neurotensin-degrading peptidase (Checler et al. 1986), and has since been 
identified in kidney, testis and liver amongst other tissues (Barelli et al. 1993; McKie et 
al. 1993; Serizawa et al. 1995). It has been shown to hydrolyze bradykinin and 
dynorphin A amongst other bioactive peptides (Swindle et al. 2013; Cavalcanti et al. 
2014). However, it was noted to share sequence and binding characteristics with pig 
soluble angiotensin binding protein (endopeptise 24.15) (McKie et al. 1993; Kato et al. 
1994) with the suggestion that it belonged to the same protein family, and therefore 
may be capable of binding AngII. Indeed, it has recently been identified as a non-AT1R, 
non-AT2R AngII binding site in brains of mice and humans (Karamyan et al. 2008; 
Wangler et al. 2012; Karamyan & Speth 2007) with functional cellular responses 
(Rashid et al. 2010; Bourassa et al. 2010). Moreover, It has been located on the inner 
membrane of rat liver mitochondria (Serizawa et al. 1995) raising the possibility of 
neurolysin acting as a novel mitochondrial AngII binding site.  
However, such a role for neurolysin seems unlikely in vivo. First, the AngII binding 
property of neurolysin has only been shown in vitro under non-physiological conditions 
(requiring activation by p-chloromercuribenzoic acid (PCMB)) (Swindle et al. 2013). 
Further, data suggests that AngII may act to inhibit neurolysin rather than being its 
natural ligand (Barelli et al. 1994; Vincent et al. 1996). Finally, AngII binding to 
83 
 
neurolysin seems to be a brain-specific phenomenon; such binding is absent in rat liver 
homogenates (Karamyan & Speth 2007).  
The mass spectrometric analysis of the mitochondrial proteome therefore failed to 
identify any canonical RAS components, nor a complete alternative system. 
Specifically, no recognised AngII receptors were identified. 
However, this could represent a false negative finding. The coverage of the 
mitochondrial proteome by mass spectrometry of the mitochondrial fraction was 
incomplete. Using an existing database of recognised rat mitochondrial proteins 
(MitoMiner – see chapter 3.2), the proportion of the known proteome identified in the 
mitochondrial fractions can be calculated (Table 5). 
 Rat 
MitoMiner 
Mass Spec 
CM 
Mass Spec 
PM 
Mass Spec 
MAM 
Number of proteins identified 1084 754 464 713 
Number of proteins in intersection 
with Rat MitoMiner 
- 330 301 244 
Percentage coverage of MitoMiner 
proteins 
- 30.4 % 27.8 % 22.5 % 
Percentage of Mass spec proteins 
Mitochondrial 
- 43.8 % 64.9 % 34.2 % 
Table 5. Assessment of the coverage of the mitochondrial proteome by mass spectrometry. CM; 
crude mitochondria, PM; pure mitochondria, MAM; mitochondria associated membranes. 
Of the total number of known mitochondrial proteins in the rat proteome, only 27.8% 
were present in the pure mitochondrial fraction. There are multiple possible 
explanations for this apparently low proteome coverage. Loss of mitochondrial proteins 
during the isolation of pure mitochondria could contribute, though given that the crude 
mitochondrial fraction only had 30.4% coverage it would appear that protein loss occurs 
before pure mitochondrial separation. 
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Alternatively, the insensitivity of mass spectrometry may have contributed to the failure 
to detect proteins that had been isolated. A number of problems can occur before and 
during mass spectrometric analysis, including poor protein solubility, selective 
adsorption, ion suppression, selective ionization and cleavage into very short peptides 
(Aebersold & Goodlett 2001).  
Sample preparation may also have led to a loss in mass spectroscopy sensitivity. 
Separating peptides from such a heavily loaded gel matrix is likely to account for a 
large portion of lost data. Greater detection may have been achieved with greater 
separation of protein bands. This can be achieved by using different gel preparations, 
or by using alternative methods of separation, such as 3D separation. By employing 
such methods a greater proportion of the mitochondrial proteome may have been 
detected. That said, the RAS proteins of interest lay predominantly in the mid to lower 
molecular range, in the section of the gel with better band separation.  
Finally, the MitoMiner database is gathered from a range of tissues and mitochondrial 
subpopulations; it is known that there is great plasticity in the mitochondrial proteome, 
both within a given population and between populations (such as exist in different 
organs and cell types) (Calvo & Mootha 2010) meaning that only a proportion of the 
total proteome will be expressed at any given time in rat liver mitochondria. Whatever 
the reason is, the low coverage allows for the possibility of RAS related proteins to be 
falsely reported as absent.  
Interestingly, this analysis also describes the purity of mitochondrial fractions separated 
using differential centrifugation and Percoll density separation. Mitochondrial proteins 
were enriched in the pure mitochondrial fraction, but this fraction also contained 35% 
non-mitochondrial proteins. Inversely, the MAM was significantly contaminated with 
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mitochondrial proteins (34.2% of total proteins). Given the proximity of ER and 
mitochondrial outer membrane at the MAM, and the tethering that occurs between the 
two, this is perhaps not surprising, but has not been previously reported.  
This also highlights the possibility that proteins identified as ‘mitochondrial’ on the basis 
of mass spectrometry of mitochondrial fractions may be false positive associations; 
30% of proteins in the pure mitochondrial fraction were non-mitochondrial.  
Whilst these data do not support the existence of a mitochondrial RAS, they cannot 
formally exclude this possibility, given the gaps in coverage of the mitochondrial 
proteome identified by SDS-PAGE separation and mass spectrometry.   
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3.2. Interrogation of existing in silico databases 
Proteomics refers to the large scale characterisation of gene and cellular functions at 
the protein level. It combines various disciplines including mass spectrometry, light and 
electron microcopy with green fluorescent protein (GFP) and gene array experiments. 
Advances in the field of proteomics over recent years have allowed for large scale 
mapping of numerous organelles and even organisms (Aebersold & Mann 2003). Data 
describing the mitochondrial proteome in a range of tissues from various organisms 
(including humans) have been published. These data have been integrated into 
databases which can be interrogated for proteins of interest. 
MitoCarta is an inventory of 1098 genes encoding proteins for which there is strong 
evidence of mitochondrial localization (Pagliarini et al. 2008). It encompasses both 
nuclear and mtDNA encoded proteins. It is generated from the mass spectrometric 
analysis of mitochondria isolated from 14 mouse tissues, with large scale GFP-tagging 
studies carried out to assess protein localisation. The human homologues to these 
genes are listed in the same database allowing for cross species comparison.  
MitoMiner is a database which combines localization data from 51 large scale GFP-
tagging and mass spectrometry studies, mitochondrial targeting sequence predictions 
and details of protein sequence and function provided by the UniProt database. The 
inventory includes data relating to 12 species, including rat and human. 
A list of RAS related gene sets from all the selected species was prepared from the 
AmiGo database (Appendix 2). These genes were cross-referenced with the MitoCarta 
and MitoMiner datasets and intersections sought. 
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Rat RAS gene intersections 
MitoMiner   
UniProt term Entry term Protein name 
P54311 GBB1_RAT Guanine nucleotide-binding protein 
subunit beta-1 
P42676 NEUL_RAT Neurolysin, mitochondrial  
Table 6. Rat RAS gene intersections. 
 
Human RAS gene intersections 
A. MitoMiner   
UniProt term Entry term Protein name 
P62873 GBB1_HUMAN Guanine nucleotide-binding 
protein subunit beta-1 
P29597 TYK2_HUMAN Non-receptor tyrosine-protein 
kinase TYK2  
Q9BYT8 NEUL_HUMAN Neurolysin, mitochondrial 
 
B. MitoCarta 
UniProt term Entry term Protein name 
P19099 C11B2_HUMAN Cytochrome P450 11B2, 
mitochondrial (Steroid 18-
hydroxylase) (Aldosterone 
synthase) 
Q9BYT8 NEUL_HUMAN Neurolysin, mitochondria  
Table 7. Human RAS gene intersections with (A) MitoMiner database and (B) MitoCarta database . 
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Mouse RAS gene intersections 
A. MitoMiner   
UniProt term Entry term Protein name 
P62874 GBB1_MOUSE Guanine nucleotide-binding 
protein subunit beta-1 
Q91YP2 NEUL_MOUSE Neurolysin, mitochondrial 
   
B. MitoCarta   
UniProt term Entry term Protein name 
P15539 C11B2_MOUSE Cytochrome P450 11B2, 
mitochondrial (Steroid 18-
hydroxylase) (Aldosterone 
synthase) 
G3UWE4 G3UWE4_MOUSE Cytochrome P450 11B2, 
mitochondrial, isoform CRA b 
Q91YP2 NEUL_MOUSE Neurolysin, mitochondrial 
P54320 ELN_MOUSE Elastin (Tropoelastin) 
Table 8. Mouse RAS gene intersections with (A) MitoMiner database and (B) MitoCarta database.  
 
Bovine RAS gene intersection 
MitoMiner   
UniProt term Entry term Protein name 
P62871 GBB1_BOVIN Guanine nucleotide-binding 
protein subunit beta-1 
P54392 NEUL_BOVIN Neurolysin, mitochondrial  
Table 9. Bovine RAS gene intersections with MitoMiner database. 
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With regard to MitoMiner RAS gene intersections, two relatively non-specific relations 
of the RAS were identified. First, the beta subunit of guanine nucleotide-binding protein 
(a G protein) was identified in all species. The beta chain is required for GTPase 
activity and for G protein-effector interactions and is therefore requisite for all G protein 
coupled receptors. As such, this protein is not specific for AngII receptors. Second, the 
non-receptor tyrosine protein kinase was identified as a human RAS gene/MitoMiner 
intersection. It is involved in intracellular signal transduction of multiple ubiquitous 
pathways including, but not exclusive to, some of those triggered by AT1R and AT2R. 
Cross reference with MitoCarta identified cytochrome P450 11B2 as a RAS related 
mitochondrial protein in both humans and mice. This enzyme is involved in aldosterone 
synthesis (its alternative name is aldosterone synthase), converting 11-
deoxycorticosterone into corticosterone, 18-hydroxycorticosterone and aldosterone, 
and as such is a target of the RAS, but is not an integral RAS protein.  
Both MitoMiner and MitoCarta identified neurolysin as a mitochondrial RAS related 
protein. However, as discussed on page 81 there is no evidence for this protein acting 
as an AngII binding site or enzyme in vivo in rat liver. 
As such, no integral members of the RAS were identified in the existing databases of 
mitochondrial associated gene products. These data support the results of mass 
spectrometry of SDS-PAGE separated mitochondrial fractions and make the existence 
of a mitochondrial RAS less likely. However, the existing databases on which both 
these analyses are based cannot exclude the presence of novel RAS component (for 
instance, a novel AngII binding site).  
  
90 
 
 
 
 
 
 
 
4. RESULTS: 
IDENTIFICATION OF 
MITOCHONDRIAL 
ANGII RECEPTORS 
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4.1. Introduction 
The concept of a functional mitochondrial RAS encompasses systems ranging from a 
complete intramitochondrial RAS, to an intramitochondrial action of imported RAS 
effector peptides, to an extramitochondrial system with direct action on the 
mitochondrion. In all these systems, RAS effector peptides must bind at the 
mitochondrion to effect their action. Identifying a binding site would confirm the potential 
for a functional mitochondrial RAS, whilst the location of this binding site on the inner or 
outer mitochondrial membrane would allow inference regarding the nature of the RAS. 
Immunochemistry is a well established technique for identifying and localizing proteins 
of interest in biological samples. However, this requires the selection of particular 
antigens of interest. With regards the RAS, this means selecting which of the known 
AngII receptors would be sought in mitochondria. 
Of the established RAS receptors, the AT1R has greatest binding affinity for AngII 
followed by the AT2R, whilst AngII is a weak agonist at the AT4R (which is not known to 
be expressed in rat liver (de Gasparo et al. 2000)). Both AT1R and AT2R are 
evolutionarily conserved (Auzan & Clauser 2009) and their expression has been 
reported on hepatic plasma and nuclear membranes (Tang et al. 1992; Booz et al. 
1992; Eggena et al. 1993; Eggena et al. 1996; Abadir et al. 2011) making these the 
most likely mitochondrial AngII receptors. 
Rodents express two AT1R subtypes; AT1A and AT1B (Sandberg et al. 1994; Kakar et al. 
1992; Iwai & Inagami 1992). They share 92-95% sequence homology and are 
pharmacologically indistinct (Speth et al. 1995; Guo & Inagami 1994). AT1A transcripts 
are predominantly expressed in all tissues except the adrenal and pituitary gland where 
the AT1B is the major subtype (de Gasparo et al. 2000). In the rat liver, reverse 
transcriptase-polymerase chain reaction (RT-PCR) evidence suggests that the relative 
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abundance of AT1A is 100% (Llorens-Cortes et al. 1994). Functionally the two subtypes 
are indistinguishable (Gasc et al. 1994). Therefore AT1A and AT1B will be jointly referred 
to as AT1R.  
Review of the literature does provide immunochemical evidence of a mitochondrial 
binding site for AngII. Immunolabelled AngII localises to the mitochondria of rat adrenal, 
liver and brain tissue (Erdmann et al. 1996) where, in the rat sensory vagal cortex at 
least, immunolabelled AT1R have been visualized (Huang et al. 2003). Meanwhile, 
immunofluorescent-tagged AT2R have been reported to co-localise with the inner 
mitochondrial membranes in rat heart and liver (Abadir et al. 2011). 
Therefore the presence of AT1R and AT2R was sought in subcellular fractions from rat 
lvier, including isolated mitochondrial inner and outer membranes. 
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4.2. Immunoblotting for mitochondrial AngII receptors  
When incubating a membrane with primary antibody, a number of factors may influence 
its specific sensitivity, i.e. how effective that antibody is in recognising the protein of 
interest. Antibody concentration, incubation environment (in particular, temperature) 
and incubation time are all influential variables. The type of primary antibody employed 
is also significant. 
There are broadly two types of primary antibody; monoclonal and polyclonal. 
Monoclonal antibodies (MAbs) are produced from a single B lymphocyte cell line in vitro 
(usually derived by fusing mammalian spleen cells with myeloma cells). Antibodies 
produced from these identical cloned cells have monovalent affinity; they all recognise 
the same epitope of the antigen. Polyclonal antibodies (PAbs) are typically produced by 
inoculating a suitable mammal with antigen which causes a polyclonal B lymphocyte 
proliferation producing a range of IgG peptides specific for various epitopes of the 
antigen. Many other nonspecific antibodies are present in the serum of these animals, 
so that on harvesting, affinity purification is used to isolate the antibodies of interest. 
There are advantages and disadvantages to using MAbs and PAbs. PAbs often have 
better sensitivity due to the fact they are generated from a large number of B 
lymphocyte clones each producing antibodies to a (different) specific epitope. However, 
affinity purification often fails to clear all background nonspecific antibodies which can 
lead to non-specific background signals on Western blotting. MAbs are highly specific 
with high purity but since they only recognise a single epitope, their sensitivity is 
decreased if there are changes in the structure of the protein (for instance, truncation, 
genetic polymorphism, glycosylation or denaturation) (Lipman et al. 2005). 
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4.2.1. Immunoblotting for AT1R in rat liver subcellular fractions 
4.2.1.1. Antibody screen 
Three commercially available antibodies to AT1R were tested against subcellular 
fractions. SDS-PAGE Western blots were performed and proteins transferred onto 
PVDF membranes. Each antibody was applied for 16 hours at 4 ˚C and 
chemilluminescence was measured as described (Methods 2.3.2). The results of these 
blots are summarised in Table 10. 
Company Antibody 
Ig 
Type 
Dilution Result 
Abcam Ab 9391 MAb 1:200 No bands detected 
Sigma Aldrich HPA003596 PAb 1:1000 
Multiple weak bands at various 
weights 
Santa Cruz Sc-1173 PAb 
1:1000 
Weak bands including  at 
expected weight 
1:500 
Stronger bands at expected 
weight 
1:200 
Well defined bands at expected 
weight 
Table 10. Results of immunoblotting with three antibodies to AT1R. Ig; immunoglobulin, MAb; 
monoclonal antibody, PAb; polyclonal antibody. 
AT1R is expressed on rat hepatocyte cell plasma and nuclear membranes, 
corresponding to the homogenate and nuclear fractions. The failure of the MAb (Ab 
9319) to detect any bands in these fractions suggests either an altered conformation of 
the AT1R leading to a change in the specific epitope that the MAb was raised against, 
or a failure in the incubation conditions. The 1:200 dilution used is a higher 
concentration than generally needed to detect proteins with a MAb, though if AT1R is 
expressed in low concentration this may lead to failure of detection. A change in the 
AT1R confirmation cannot be ruled out.  
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The multiple bands resolved with HPA003596 at various molecular weights suggest 
cross reactivity with non-target proteins, likely a consequence of large amounts of non-
specific antibody in the antiserum ineffectively cleared by affinity purification.  
Sc-1173 gave the most promising results and was used for all subsequent 
immunoblotting at a concentration of 1:200, applied for 16hours in 5% BSA at 4 ˚C. 
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4.2.1.2. SDS-PAGE Western blots for AT1R in rat liver subcellular fractions 
 
Figure 16. Western blot detection of AR1R in subcellular fractions. (A) Sc-1173 produced a band at 
approximately 43 kDa in the CM and MAM fractions but not the PM. (B) CoxIV was employed as a 
mitochondrial marker. H; homogenate, N; nuclear, CM; crude mitochondria, PM; pure mitochondria, 
PK; proteinase K digest, IMM: inner mitochondrial membranes, Mx; mitochondrial matrix, MAM; 
mitochondrial associated membrane, Mc; microsomes, L; lysosomes, Cyt; cytosol.  
Employing Sc-1173 as the primary antibody revealed a band at approximately the 
expected molecular weight of AT1R (43 kDa). This band was present in increasing 
density in the homogenate, nuclear and crude mitochondrial fractions, in keeping with a 
mitochondrial protein. However, the 43 kDa band was not present in any of the pure 
mitochondrial fractions (pure mitochondria, proteinase K digest, inner mitochondrial 
membranes or mitochondrial matrix) but an enriched band in the MAM fraction was 
observed. There was also a band visible in the lysosomal fraction and to a lesser extent 
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the microsomal and cytosolic fractions. There was minor mitochondrial contamination, 
evidenced by the very faint CoxIV bands in non-mitochondrial subfractions. 
Further blots were performed on subcellular fractions isolated from three separate rat 
livers (n = 3) excluding mitochondrial subfractions, allowing for greater enrichment of 
the PM and MAM fraction.  
 
Figure 17. Representative blot showing immunostaining for AT1R with Sc-1173. Immunoreactive 
bands at the expected weight of AT1R (43 kDa) were present in all fractions other than the pure 
mitochondria. CoxIV was used as a mitochondrial marker. H; homogenate, N; nuclear, CM; crude 
mitochondria, PM; pure mitochondria, MAM; mitochondria associated membrane, Mc; microsomes, 
L; lysosomes, PL; post-lysosomal supernatant, Cyt; cytosol. 
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Figure 18. Composite figure of AT1R staining patterns in 3 liver preparations. Subcellular fractions 
from 3 livers (A, B and C, n=3) were run on SDS-PAGE and immunostained for AT1R with Sc-1173. 
Immunostaining with CoxIV as a mitochodnrial marker was carried out on each membrane.  H; 
homogenate, N; nuclear, CM; crude mitochondria, PM; pure mitochondria, PK; proteinase K digest, 
IMM; inner mitochondrial membranes, Mx; mitochondrial matrix, MAM; mitochondria associated 
membrane, Mc; microsomes, L; lysosomes, PL; post-lysosomal supernatant, Cyt; cytosol.  
In all three blots the same pattern of AT1R staining was seen, with bands at 43 kDa in 
CM and MAM fractions but not in the PM fraction. CoxIV staining confirmed adequate 
mitochondrial protein in the PM lane. This suggests AT1R presence in the MAM but not 
in pure mitochondria.  
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4.2.1.3. Validation of Sc-1173 specificity for AT1R 
In order to draw conclusions regarding AT1R subcellular location based on Western 
blots with Sc-1173, the specificity of the antibody was tested using a selective AT1R 
small-interfering RNA (siRNA). Successful silencing of the AT1R gene results in a 
decreased expression of AT1R protein which should be reflected on Western blots as a 
decreased intensity of the 43 kDa band seen with Sc-1173. 
Cell cultures of HepG2 cells (of human hepatocellular origin) in 6 well plates were 
incubated with AT1R siRNA (#29750, Santa Cruz, Texas, USA)  non-targeting siRNA 
(#D0012100205, Dharmacon, GE Healthcare, Buckinghamshire, UK) , or no siRNA 
(untransfected) as described in Methods section 2.6.2. Selective p53 siRNA (#29435, 
Santa Cruz, Texas, USA) was used as a control for successful transfection. Cells were 
harvested at 48 hours post transfection and whole cell lysates prepared for SDS-PAGE 
Western blotting using Sc-1173 to immunoblot AT1R and Sc-DO-1 for p53. β-actin (Sc-
47778) was employed as a loading control. All antibodies were supplied by Santa Cruz 
(Texas, USA).  
 
Figure 19. Western blots of AT1R and p53 siRNA silencing in HepG2 cells. (A) AT1R gene silencing; 
immunoblotting with Sc-1173 revealed bands at 43 kDa in the untransfected (UT) and scrambled 
siRNA (Sc) samples. In cells exposed to selective AT1R siRNA no decrease in the intensity of the 43 
KDa band was seen. (B) p53 gene silencing; immunoblotting with Sc-DO-1 revealed successful p53 
gene silencing reflected in the decreased intensity of the 50 kDa band in cells exposed to the 
specific p53 siRNA. (C) Loading control using antibody against β-actin revealed equal loading in all 
wells.  
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There are a number of possible explanations for these data. First, transfection of AT1R 
siRNA may not have been successful. This possibility is made less likely by the 
successful gene silencing of p53 using the same protocol suggesting the transfection 
protocol was effective. Secondly, the time allowed for silencing of the AT1R gene by 
successfully transfected siRNA (48 hours) may have been insufficient. Refuting this 
argument are data showing that in Human Embryonic Kidney 293 (HEK293) and 
immortalized Proximal Tubule Cells (PTCs) AT1R protein is down-regulated in response 
to AT1R siRNA within 24 hours and maximally at 48hrs (Li & Zhuo 2007) whilst in 
HepG2 cells transfected with AT1R siRNA (Santa cruz SASI_Hs02_00206672) and 
harvested at 48 hours, an 80% reduction in AT1R mRNA was demonstrated 
(Nabeshima et al. 2009). An alternative explanation in that AT1R protein may have 
been successfully down regulated but this was not apparent due to non-specificity of 
Sc-1173. 
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4.2.2. Immunoblotting for AT2R in rat liver subcellular fractions 
4.2.2.1. Antibody screen 
Two candidate commercial antibodies raised against AT2R were tested in an antibody 
optimisation process. Subcellular fractions were run on SDS-PAGE and transferred to 
PVDF membranes. Each antibody was incubated with the membrane in 5% BSA for 16 
hours at 4 ˚C. The predicted weight of AT2R is 41 kDa, though the observed in vitro 
weight is closer to 50 kDa. 
Company Antibody Ig Type Dilution Result 
Abcam Ab 19134 PAb 1:200 
Weak bands detected 
with none at 41- 50 kDa 
Santa Cruz Sc-9040 PAb 1:200 
Multiple intense bands 
detected including at  
41 - 50 kDa 
Table 11. Results of immunoblotting with two antibodies to AT2R (expected MW 41 - 50 kDa). Ig; 
immunoglobulin, MAb; monoclonal antibody, PAb; polyclonal antibody. 
Ab 19134 displayed non specificity and poor sensitivity. As such, Sc-9040 was chosen 
for all further blots. 
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4.2.2.2. SDS-PAGE Western blots for AT2R in rat liver subcellular fractions 
 
Figure 20. Representative blot showing immunostaining for AT2R with Sc-9040. Multiple bands were 
detected in all fractions including bands at the approximate weight of AT2R (41 KDa). H; 
homogenate, CM; crude mitochondria, PM; pure mitochondria, MAM; mitochondria associated 
membranes, Mc; microsomes, L; lysosomes, Cyt; cytosol.  
 
Figure 21. AT2R panels from 3 separate liver isolations. Images have been cropped to include all 
immunoreactive bands around the expected weight of AT2R (41 kDa). H; homogenate, N; nuclear, 
CM; crude mitochondria, PM; pure mitochondria, PK; proteinase K digest, IMM; inner mitochondrial 
membranes, Mx; mitochondrial matrix, MAM; mitochondria associated membranes, Mc; 
microsomes, L; lysosomes, Cyt; cytosol. CoxIV was used as a mitochondrial marker. 
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The staining pattern with Sc-9040 suggests low specificity of the polyclonal antibody, or 
the contaminating presence of antibodies directed against non-target proteins. 
Interpreting these blots further is therefore unsafe. 
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4.3. Identification of immunoreactive proteins by mass spectrometry 
4.3.1. Immunoprecipitation of mitochondrial AngII receptors 
Definitive identification of proteins in immunoreactive bands visualized with both Sc-
1173 (AT1R) and Sc-9040 (AT2R) was sought by mass spectrometry of the SDS-PAGE 
gel bands.  
The detection limit of a mass spectrometer for a particular protein is governed by the 
molar mass of that protein and is generally in the femtomole range. For proteins less 
than 75 kDa this corresponds to 2-5 nanograms. It is very common for gel bands to 
contain many different proteins, so that the protein of interest may be present in only 
small amounts. Increasing the amount of protein loaded in each well would help in this 
situation, but this is limited by the volume capacity of each well. Immunoprecipitation of 
proteins affords a way in which to purify the protein of interest, allowing an increased 
amount to be run on gels and thus increasing the sensitivity of detection with mass 
spectrometry. 
Subcellular fractions (400 µg) isolated from the livers of 12-week old male Sprague-
Dawley rats were used as input in the immunoprecipitation protocol (see Methods 
chapter 2.5). The supernatant from each input was incubated with Sc-1173 or Sc-9040 
for 16hours at 4 ˚C. The elute produced was run on SDS-PAGE. 
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4.3.1.1. Immunoprecipitation of AT1R with Sc-1173 
 
 
Figure 22. Coomassie Brilliant Blue stain of 10% Bis-Tris gel following immunoprecipitation of AT1R 
from subcellular fractions with Sc-1173. Each lane was loaded with 40 µg of immunoprecipitant. A 
single band is visible in the MAM fraction near the expected weight of AT1R (43 KDa) which does 
not appear in the other fractions. H; homogenate, CM; crude mitochondria, PM; pure mitochondria, 
MAM; mitochondria associated membranes, Mc; microsomes, L; lysosomes, and C; cytosol. 
The heavily stained band at c.120 kDa is due to non-denatured IgG present in the 
sample, whilst the heavy chain of the Ig appears at 75 kDa and the light chain at 20 
kDa. A well-defined band is seen in the MAM fraction just below 37 kDa. To increase 
the quantity of protein in this band, further immunoprecipitation was conducted in the 
MAM fraction alone, using a greater amount of MAM as the input and loading 50 µg 
immunoprecipitant in the well of the gel. 
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Figure 23. Coomassie Brilliant Blue staining of 10% Bis-Tris gel following immunoprecipitation of 
AT1R from MAM with Sc-1173. MAM; mitochondria associated membrane, IP; immunoprecipitation. 
On immunoprecipitation of AT1R from the MAM, a single band was seen at 
approximately 35 kDa. This band was present in the input and absent in the output, in 
keeping with effective immunoprecipitation. The weight of the band is lower than the 
expected weight of AT1R (43 kDa). However, truncated forms of AT1R have been 
described (Cook & Re 2009; Cook et al. 2007; Conchon et al. 1999) and a cleavage 
site has been identified that cleaves the complete receptor into 6 kDa and 37 kDa 
fragments (Cook et al. 2011) suggesting this band could be a truncated form of the 
receptor. 
Both bands were cut from the 2D gel and sent for analysis at the Taplin mass 
spectrometry facility at Harvard Medical School (MA, USA).  
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4.3.1.2. Immunoprecipitation of AT2R with Sc-9040 
 
 
Figure 24. Coomassie Brilliant Blue staining of 10% Bis-Tris gel following immunoprecipitation of 
AT2R from subcellular fractions with Sc-9040. Each lane was loaded with 40 µg of 
immunoprecipitant. H; homogenate, CM; crude mitochondria, PM; pure mitochondria, MAM; 
mitochondria assocaited membranes, Mc; microsomes, L; lysosomes, and C; cytosol. 
Following immunoprecipitation of AT2R using Sc-9040, excluding bands accounted for 
by IgG heavy and light chains, three distinct bands were seen. Bands at 75 kDa (band 
3) and 40 kDa (band 4) were present in all fractions, whilst a band just below 35 kDa 
(band 5) was visible in MAM only.  
All three bands from the MAM fraction were cut from the gel and analysed by mass 
spectrometry at the Taplin mass spectrometry facility at Harvard Medical School (MA, 
USA).
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4.3.2. Mass spectrometry of AT1R gel bands 
Gel fragments were analysed by mass spectrometry (Taplin biological mass spectrometry facility, Harvard medical school, MA, 
USA). Any protein with three or more unique peptide matches was considered ‘confidently’ identified in the sample. Proteins with less 
than three unique peptide matches are not considered to be confidently identified without further confirmation. 
Protein name Unique 
peptide 
matches 
% coverage Location Function 
Uricase 20 48.5% Peroxisome/mitochondrion Catalyzes the oxidation of uric acid to 5-
hydroxyisourate, which is further processed to 
form (S)-allantoin. 
60S acidic ribosomal 
protein P0 
2 6.9% Cytoplasm/nucleus Ribosomal protein  
Actin, aortic smooth 
muscle 
2 6.9% Cytoplasm/nucleus Actins are highly conserved proteins, are 
involved in various types of cell motility and 
ubiquitously expressed in all eukaryotic cells. 
Tubulin beta-2A 
chain 
1 2.2% Cytoplasm Tubulin is the major constituent of 
microtubules. It binds two moles of GTP, one 
at an exchangeable site on the beta chain and 
one at a non-exchangeable site on the alpha 
chain 
Table 12. Mass spectroscopy of gel band 1. Proteins with ≥ 3 unique peptide matches are considered to be identified with confidence. No AT1R related 
peptides were identified.  
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Protein name Unique 
peptide 
matches 
% 
coverage 
Location Function 
Uricase 23 52.8% Peroxisome/mitochondrion Catalyzes the oxidation of uric acid to 5-
hydroxyisourate 
Peroxiredoxin-1 7 32.7% Cytoplasm Involved in redox regulation of the cell 
Heterogeneous 
nuclear 
ribonucleoproteins 
A2/B1 
5 15.6% Cytoplasm/nucleus/spliceosome  Involved with pre-mRNA processing 
60S acidic 
ribosomal protein 
P0 
2 6.9% Cytoplasm/nucleus Ribosomal protein  
Heterogeneous 
nuclear 
ribonucleoprotein 
A3 
2 3.4% Nucleus/spliceosome Plays a role in cytoplasmic trafficking of RNA. 
Binds to  
the cis-acting response element, A2RE 
Arginase-1 2 4.6% Cytoplasm Catalyses the reaction: L-arginine + H2O = L-
ornithine + urea. 
F-actin-capping 
protein subunit 
alpha-1 
1 3.5% Cytoplasm F-actin-capping proteins bind in a Ca2+-
independent manner to the fast growing ends of 
actin filaments 
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Protein name Unique 
peptide 
matches 
% 
coverage 
Location Function 
Peroxiredoxin-4 1 4.0% Cytoplasm/secreted Probably involved in redox regulation of the cell. 
Peroxiredoxin-2 1 5.6% Cytoplasm Involved in redox regulation of the cell. Reduces 
peroxides with reducing equivalents provided 
through the thioredoxin system 
L-lactate 
dehydrogenase A 
chain 
1 2.7% Cytoplasm Catalyses the reaction: (S)-lactate + NAD+ = 
pyruvate + NADH 
Table 13. Mass spectroscopy of gel band 2. Proteins with ≥ 3 unique peptide matches are considered to be identified with confidence. No AT1R related 
peptides were identified
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4.3.3. Mass spectrometry of AT2R gel bands 
All three bands from the immunoprecipitated MAM fraction were analysed by mass spectrometry. No peptide matches were found in 
band 3 (at 75 kDa). Peptide matches in the other bands are details in tables 14 and 15.  
 
Protein name Unique 
peptide 
matches 
% coverage Location Function 
Uricase 8 23.8% peroxisome/mitochondrion Catalyzes the oxidation of uric acid to 5-
hydroxyisourate, which is processed to form 
allantoin. 
Table 14. Mass spectroscopy of gel band 4 (40 KDa band). Proteins with ≥ 3 unique peptide matches are considered to be identified with confidence. 
No AT2R related peptides were identified. 
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Protein name Unique 
peptide 
matches 
% coverage Location Function 
Actin, aortic smooth 
muscle 
7 21.8% cytoplasm/nucleus Actins are highly conserved proteins that are 
involved in various types of cell motility and are 
ubiquitously expressed in all eukaryotic cells. 
Actin, cytoplasmic 1 4 12.0% cytoplasm/cytoskeleton Actins (see above) 
Uricase 2 7.6% peroxisome/mitochondrion Catalyzes the oxidation of uric acid to 5-
hydroxyisourate, which is processed to form 
allantoin. 
40S ribosomal 
protein S9 
2 8.8% cytoplasm Identified in a IGF2BP1-dependent mRNP 
granule complex containing untranslated mRNAs 
Betaine--
homocysteine S-
methyltransferase 1 
2 4.4% cytoplasm Involved in the regulation of homocysteine 
metabolism. Converts betaine and homocysteine 
to dimethylglycine and methionine, respectively. 
Table 15. Mass spectrometry of gel band 5 (35 KDa band). Proteins with ≥ 3 unique peptide matches are considered to be identified with confidence. No 
AT2R related peptides were identified. 
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4.4. Conclusions 
In these experiments, the presence of a recognised AngII receptor was sought in rat 
liver mitochondria. Western blotting with specific antibodies was employed. Several 
antibodies against AT1R were screened. The monoclonal antibody (ab 9391) did not 
reveal any protein at the expected weight of the receptor (43 kDa) whilst the 
polyclonal HPA003596 did show some chemiluminescent bands but they were at 
several molecular weights and the signal was weak. Optimisation of conditions 
using Sc-1173 produced a defined band at 43 kDa. This band was present in the 
crude mitochondrial fraction and the MAM but not in pure mitochondrial fractions. 
The specificity of the antibody could not be proven by siRNA silencing of the 
receptor and so mass spectrometry of the immunoprecipitated band was performed 
to confirm the presence of AT1R peptides. No such peptides were found. 
The pattern of immunoreactive bands visualized with the chosen AT2R antibody (Sc-
9040) suggested non-specificity, with multiple bands even in the region of the 
expected weight of the target protein. Immunoprecipitation produced bands at 75 
kDa, 40 kDa and 35 kDa. The 75 kDa and 40 kDa bands were present in all 
subcellular fractions, whilst a 35 kDa band was only visualized in the MAM fraction. 
All three bands were subjected to mass spectrometry. No peptides were identified in 
the 75 kDa band whilst no AT2R-specific peptides were identified at 40 kDa or 35 
kDa. 
The failure to identify AngII receptor proteins in the immunoreactive bands by mass 
spectrometry is either a ‘false negative’ result due to the abundance of the receptor 
falling below the sensitivity threshold of the spectrometer, or a ‘true negative’ due to 
non-specificity of the antibodies employed.  
Immunoreactive bands were visualized in Tris-Bis gels using Coomassie brilliant 
blue staining which has a detection limit of approximately 50 ng. The sensitivity of 
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the mass spectrometer varies according to molar mass, but in general equates to 2-
5 ng for proteins less than 75 kDa. As such, proteins clearly visualised with 
Coomassie brilliant blue should be detected in the mass spectrometer. Since the 
fractions run on the analysed gel contained only proteins selected by 
immunoprecipitation this suggests non-specificity of the antibodies. 
The Sc-1173 immunoglobulin is an affinity purified rabbit polyclonal antibody. It is 
targeted against a non-specified peptide from the N-terminal extracellular domain of 
the human AT1R, with specificity described for human, mouse and rabbit in 
applications including Western blot and immunoprecipitation. Many groups have 
published data using Sc-1173, though often without providing evidence of its 
specificity in their laboratories. Those that have provided evidence of specificity 
have relied upon pre-adsorption tests in which a synthetic peptide corresponding to 
the specific epitope recognised by the antibody is incubated with the antibody to 
block binding (as a negative control) (Harrison-Bernard et al. 1999; Zhuo, Carretero, 
et al. 2006; Zhuo, Li, et al. 2006). However, binding to the synthetic antigen does 
not equate to specificity for the receptor; Rateri et al showed strong binding of Sc-
1173 to immunising peptide but were unable to demonstrate any specific interaction 
with the AT1R (Rateri et al. 2011). This is particularly pertinent for antibodies that 
have already been affinity purified, since such an antibody has been produced by 
screening for its binding to the target epitope and will therefore always bind it and 
always pass an pre-adsorption test whether specific for the protein or not (Saper 
2009). 
An important study of the specificity of commercially available AT1R antibodies, 
published after I had completed the work described, confirms my findings that many 
commercially-available antibodies may be highly non-specific in their binding 
characteristics. Benicky et al screened six antibodies including Sc-1193 and 
ab9391. Using AT1R knockout animals (that do not express any AT1R) they showed 
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all six antibodies recognise proteins of similar size to AT1R, but produced identical 
immunostaining patterns in Western blots from wild-type and AT1R knockout mice 
(Benicky et al. 2012). They concluded that none of the commercially available 
antibodies tested were specific for AT1R in rodents. Similar conclusions were drawn 
in testing of newly developed non-commercial AT1R antibodies (Rateri et al. 2011). 
Similarly, there is now good evidence to suggest that commercially available AT2R 
antibodies are also non-specific. Sc-9040 is a polyclonal antibody raised in rabbit 
against a protein corresponding to amino acids 221-363 of the AT2R of human 
origin. It is quoted as having specificity in human, mouse and rat tissues in 
applications including Western blots and immunoprecipitation. In a study by Hafko 
et al, the specificity of Sc-9040 along with two other commercially available and 
commonly employed AT2R antibodies was tested. In both mouse and rat tissue 
extracts multiple immunoreactive bands were observed and there was no 
correlation between the observed immunoreactivity and the presence or absence of 
the AT2R protein, receptor binding or gene expression (Hafko et al. 2013). 
On review of the available literature, there is no convincing evidence of 
mitochondrial AT1R or AT2R using antibodies with proven specificity. Of particular 
note, Abadir et al described mitochondrial AT2R in liver using Sc-9040 for Western 
blots and an alternative antibody (sc 48451) for immunochemistry for which no 
evidence of specificity was provided. 
With regards the presence of an AngII binding site in liver mitochondria, these data 
do not exclude this possibility. Specific antibodies to AT1R and AT2R may have 
enabled their isolation and identification with the methods employed here. 
Alternatively, a novel AngII receptor may be present. As concluded by Hafko and 
Benicky, in the absence of specific antibodies, the gold standard method for 
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identification of ligand binding sites is competitive radioligand binding assays 
(Benicky et al. 2012; Hafko et al. 2013). 
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5. RESULTS: 
RADIOLIGAND 
BINDING STUDIES 
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5.1. Introduction 
Mass spectrometry of both the mitochondrial proteome and bands resulting from the 
targeted immunoprecipitation of AngII receptors failed to identify any mitochondrial 
AngII binding site. However, a receptor in low abundance may not have been 
detected by whole proteome mass spectrometry, whilst the non-specificity of AT1R 
and AT2R antibodies undermined the attempt to use immunochemistry to isolate 
them.  
Radioligand binding assays provide an alternative way of investigating the presence 
and characteristics of any mitochondrial AngII binding site and are regarded as the 
gold standard technique in the study of membrane receptors (Jensen et al. 2009; 
Hafko et al. 2013; Benicky et al. 2012; Saper & Sawchenko 2003). Ligands with 
high specific activity allow receptors that are usually expressed in low densities to 
be characterized. Binding assays provide a quantification of the interaction between 
these ligands and their receptors, encompassing receptor binding affinity and 
population density. When specific receptor antagonists are available, radioligand 
binding assays can additionally identify receptor subtype. 
Radioiodinated AngII ([125I]-AngII) has been used for decades to investigate the 
binding properties of AngII in various tissues. There are some data reporting [125I]-
AngII binding in subcellular fractions. Sirett et al investigated subcellular [125I]-AngII 
binding in rat brain homogenates and reported 18.2% of total specific binding in the 
mitochondrial fraction (Nancy E. Sirett et al. 1977) whilst van Kats et al reported 
[125I]-AngII binding in the mitochondrial fractions of pig kidney and adrenal glands 
(van Kats et al. 2001). However, these studies were performed with crude 
mitochondrial fractions and so do not clarify whether AngII binds to mitochondria 
themselves or to associated membranes (MAM).  
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Radioligand binding studies were carried out with subcellular fractions, first to 
confirm binding of AngII in crude mitochondria, then to clarify whether this binding 
occurred at the mitochondrion or MAM.  
These studies were carried out in collaboration with Dr Anthony Davenport of the 
Clinical Pharmacology Unit, University of Cambridge with the direction of the work 
determined through regular discussions between us. I prepared all membrane 
samples at University College London and performed protein quantification. Due to 
the highly skilled nature of this technique, Dr Davenport and his colleague Dr Rhoda 
Kuc then performed the experiments. 
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5.2. Optimisation of ligand binding assays 
For saturation assays, the concentration of [125I]-AngII had to be chosen empirically 
since no data exist regarding the affinity of binding to liver mitochondrial fractions. 
Additionally, the length of time and temperature for incubation of liver subfractions 
with [125I]-AngII had to be optimised. Experiments confirmed incubation for 1 hour at 
room temperature (22C) with 0.5 nM [125I]-AngII provided optimum binding 
conditions. 
Under these conditions, specific binding of [125I]-AngII was measured in liver 
homogenates. Specific binding was detected with a KD of 0.69 ± 0.3 nM. This 
binding affinity is similar to that seen in human heart (Nozawa et al. 1994) and 
greater than values reported in the literature for whole rat liver homogenates 
(Karamyan et al. 2009) suggesting appropriate conditions to perform further 
experiments. 
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5.3. Specific binding of [125I]-AngII in crude mitochondria from rat 
liver 
 
 
KD  
(nM) 
BMAX (fmol/mg) 
Rat 1 0.43 ± 0.41 6.82 ± 4.3 
Rat 2 0.51 ± 0.49 4.60 ± 3.6 
Rat 3 0.34 ± 0.32 3.73 ± 2.8 
Pooled data 
n=3 
0.59 ± 0.33 5.05 ± 1.1 
 
Table 16. Specific binding of [
125
I]-AngII in crude mitochondrial fractions isolated from livers of 
12-week old male Sprague Dawley rats. Data represent mean ± SD.  
These data confirm binding of [125I]-AngII in rat liver crude mitochondrial fractions 
with a specific binding affinity in the same range as AngII binding at the plasma 
membrane and with a receptor density consistent with functional G protein-coupled 
membrane receptors (Karamyan et al. 2009; Nozawa et al. 1994).   
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5.4. Specific binding of [125I]-AngII in pure mitochondria and MAM 
In order to measure specific binding in pure mitochondria and MAM, combined 
subfractions from 5 individual rats were required for each assay. Data presented 
represent three independent experiments each with pooled (x 5) membranes. 
 
Pooled data 
(n=3) 
KD  
(nM) 
BMAX  
(fmol/mg) 
nH 
PM 0.38  0.30 0.42  0.06 0.90  0.17 
MAM 0.28  0.12 15.34  5.1 1.01  0.03 
 
Table 17. [
125
I]-AngII saturation binding in pure mitochondria and MAM. Pooled (x5) 
mitochondrial membrane preparations for MAM and PM were used to measure saturation 
binding. Assays were performed in triplicate. PM; pure mitochondria, MAM; mitochondria 
associated membranes. Data represent mean ± SD. 
Specific binding of [125I]-AngII with high affinity was observed in both pure 
mitochondria and MAM. The Hill coefficient close to 1 is indicative of either a single 
population of AngII receptors or multiple populations of receptors with similar affinity 
for [125I]-AngII. Since AngII shows 15 fold selectivity for AT2R over AT1R (Bosnyak et 
al. 2011), these data would favour the presence of a single AngII receptor type. 
Though the BMAX for [
125I]-AngII in MAM is high, that for the specific binding in pure 
mitochondria is below that usually considered consistent with a functional receptor 
system. The most likely explanation for this is contamination of pure mitochondrial 
fractions with MAM. 
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5.5. Identification of AngII receptor type in pure mitochondria and 
MAM 
Having determined the KD for [
125I]-AngII in crude mitochondrial subfractions, 
competition binding assays were performed using specific antagonists at the AT1R 
(losartan) and AT2R (PD123319).  
 
Figure 25. [125I]-AngII specific binding in MAM and pure mitochondrial fractions in the 
presence of AT1R and AT2R antagonists. MAM or pure mitochondria (PM) were incubated with 
[
125
I]-AngII for 1 hour at room temperature (22 ˚C), with or without the addition of Angiotensin-II 
(10 µM) to determine non-specific binding. Additionally, either losartan (1 µM) or PD123319 (1 
µM) were included to determine presence of AT1R vs. AT2R receptors. Data are presented as 
percentage of specific binding in each fraction. Data are plotted as mean ± SD. 
In the MAM, specific binding was completely inhibited by incubation with the AT1R 
receptor antagonist losartan whilst PD123319 did not significantly reduce binding. 
Similar findings were observed in the pure mitochondrial fraction.   
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5.6. Conclusions 
These data show that in rat hepatocytes, radiolabelled AngII binds specifically and 
with high affinity to receptors in the MAM and pure mitochondria, but only in the 
MAM is the density of receptors compatible with a functioning receptor system. 
Further, these receptors are likely AT1R since the Hill coefficient suggested a single 
receptor subtype and binding was completely inhibited by the AT1R selective 
inhibitor, losartan. The binding in pure mitochondria is likely a consequence of 
contamination of the PM fraction with MAM membranes, supported by the data 
presented in Table 5 (p.82), suggesting contamination is inherent to the isolation 
protocol. 
These findings contradict other published reports. Of the studies identifying 
mitochondrial [125I]-AngII binding, Sirett studied brain tissue whilst van Kats used 
renal and adrenal tissue; the possibility that mitochondrial AngII receptors exist in 
these tissues cannot be excluded. However, of note van Kats used a crude 
mitochondrial fraction to measure mitochondrial binding (therefore consistent with 
the data presented in this chapter) and noted significant lysosomal contamination 
(van Kats et al. 2001). In Sirett’s study, the BMAX of [
125I]-AngII binding in the 
mitochondrial fraction was 1.28 fmol/mg suggesting very sparsely distributed 
receptors, again raising the possibility of contamination (Nancy E. Sirett et al. 1977). 
Importantly in reference to the findings of Abadir et al (Abadir et al. 2011), these 
radioligand binding studies provide no evidence for AT2R in mitochondria. 
There are limitations to ligand binding assays which should be considered. These 
assays were carried out under non-physiological conditions (room temperature) so 
may not accurately represent pharmacokinetics in vivo. Additionally the intracellular 
environment contains endopeptidases which metabolise AngII. This has two 
consequences for radioligand binding studies. In homogenates, [125I]-AngII is 
metabolically degraded to [125I]-AngIII which also binds AT1R and AT2R making 
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accurate measurement of [125I]-AngII binding difficult (Karamyan et al. 2009). 
Conversely, in mitochondrial isolates (lacking cytoplasm) the usual in vivo 
degradation does not occur making it an inaccurate representation of cellular 
physiology. It cannot be excluded that the described effects of AngII on 
mitochondria within cellular environments are due to angiotensin fragments. 
However, it is unlikely that a complete mitochondrial RAS would operate 
independent of AngII action at a receptor, making this possibility unlikely. 
A further consideration is that it remains unclear whether [125I]-AngII is able to cross 
the mitochondrial membrane. As such, if an AngII binding site existed within the 
inner mitochondrial membrane or matrix, this may not bind radioligand causing a 
false negative result. To explore this possibility, further experiments could be 
performed using inner mitochondrial membrane preparations pooled from a large 
number of livers (approximately 20 per assay).  
The presence of AT1R in MAM fractions in high density requires explanation. Two 
scenarios seem most likely; they represent receptors being trafficked to or from the 
plasma membrane or other intracellular organelles via the MAM, or they are 
functioning receptors for AngII in a MAM-mitochondrion microdomain.  
With regards the former, the general model of G protein-coupled receptor trafficking 
involves initial transport to the ER where they undergo processing and folding 
(Drake et al. 2006). Given MAM is ER membrane that is transiently and dynamically 
associated with mitochondria (Bravo et al. 2011; Rizzuto et al. 1998; Hamasaki et 
al. 2013), the AT1R present in these studies may represent receptors being 
trafficked through the ER.  
The counter-argument is that MAM AT1R are present by design rather than 
coincidence. It seems unlikely that such high density of receptors would be found if 
they were solely being trafficked, whilst it is accepted that the proteome of the MAM 
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is regulated independent of the rest of the ER allowing for such concentration of 
proteins. Evidence to support this hypothesis would be provided by performing [125I]-
AngII radioligand binding studies with (non-mitochondrial associated) ER and 
compare receptor density to that found in the MAM; if significantly lower in the ER it 
would suggest programmed accumulation in the MAM.  
The possibility remains, therefore, that MAM AT1Rs are part of a functional MAM-
mitochondrial RAS. Direct interaction of MAM receptors and proteins of the 
mitochondrial OMM have been well described (Szabadkai et al. 2006; Csordás et al. 
2006). Even if a direct communication between AT1R and OMM is not apparent, 
given the range of signalling cascades that the AT1R induces upon activation, it is 
conceivable that second messengers may effect a crosstalk with mitochondria. The 
IP3 - IP3R - Ca
2+ - VDAC signalling system would provide such a link. The MAM-
mitochondrial Ca2+ signalling pathway is a target of many signalling cascades 
(Hayashi & Su 2007) and is largely orchestrated through the IP3R. Since activation 
of AT1R is known to induce IP3 release (Montezano et al. 2014) activation of such a 
system is plausible. Given the known effects of Ca2+ in modulating mitochondrial 
bioenergetics and ROS production (see Introduction, Chapter 1.9, p.40), activation 
of MAM AT1R could allow the rapid tuning of mitochondrial metabolism. Assessment 
of alterations in mitochondrial respiration in the presence of AngII was therefore 
carried out. 
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6. RESULTS:       
EFFECT OF ANGII ON 
RESPIRATION OF 
ISOLATED LIVER 
MITOCHONDRIA 
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6.1. Introduction 
Published data convincingly support an effect of AngII on aspects of mitochondrial 
physiology (see Introduction Chapter 1.10, p.41). However, most studies have 
assessed mitochondria within their intact cellular environment, or mitochondria 
isolated from tissues following administration of AngII in animal models. 
Disentangling plasma receptor- or nuclear receptor- mediated effects from direct 
mitochondrial effects is not possible in these experimental designs. 
Results of the radioligand binding studies taken together with the mass 
spectroscopy data make conventional action of AngII on the AT1R or AT2R at the 
mitochondrion unlikely. However, the possibility of AngII acting directly in a non-
canonical fashion remained a possibility. A direct effect on ETS complex function, 
membrane permeability (LEAK state) or intra mitochondrial metabolic pathways 
(such as the TCA cycle or β oxidation) could result in functional modulation. 
Such effects should be evident in oxygen consumption studies with isolated 
mitochondria exposed to AngII. Of note, Abadir et al showed an overall decrease in 
State 3 respiration in isolated rat liver mitochondria in response to the synthetic 
AT2R agonist CGP421140, an effect they suggested was linked to an increase in 
mitochondrial NO production (Abadir et al. 2011).  
To investigate whether such effects could be shown using the endogenous agonist 
(AngII), crude mitochondria were isolated from 12-week old male Sprague Dawley 
rats and their oxygen consumption measured under various experimental 
conditions. Pure mitochondria were not used in these experiments since Percoll 
density separation by ultracentrifugation renders mitochondria dysfunctional whilst 
only crude mitochondria would allow for investigation of MAM-mitochondrial 
interactions (data not shown). 
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6.2. Effect of AngII on ‘resting’ isolated liver mitochondria 
To investigate the effect of AngII on basal respiration, O2 consumption of isolated 
mitochondria was measured in the absence (control) and presence of 1 µM AngII 
with no additional substrates or ADP. Measurements were taken at baseline and 5, 
10, 15, 20 and 25 minutes following the addition of AngII or vehicle (water). 
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Figure 26. Basal respiration rates in isolated mitochondria with and without (control) 1 µM 
AngII. Data plotted as means ± SEM (n = 9). Differences along time between samples were 
assessed by ANOVA for repeated measures (time-group interaction: p >0.05). 
There was no effect of 1µM AngII on respiration of unstimulated isolated liver 
mitochondria over the course of a 25 minute incubation. In the absence of 
exogenous substrates or ADP, mitochondria respire on endogenous substrates with 
ATP cycling by extra-mitochondrial ATPase activity. This is reflected in the decrease 
in respiratory rate observed over time, implying consumption of available substrates. 
However, the ongoing (though low) rate of respiration at 25 minutes suggests a 
residual O2 consumption. If it assumed all endogenous substrates have been 
consumed by this point, this represents mitochondrial non-ETS O2 utilisation in side 
reactions that result in superoxide anion radicals and other reactive oxygen species 
(Cadenas & Davies 2000). From these data it can be concluded that AngII does not 
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increase this non-ETS O2 utilisation, and therefore suggests in the resting state, 
AngII is unlikely to increase mitochondrial ROS production. 
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6.3. Effect of AngII on OXPHOS in isolated liver mitochondria 
Since no effect of AngII on unstimulated mitochondria could be identified, an effect 
on actively respiring mitochondria was sought. Mitochondria were incubated in the 
respiration chamber at 37 ˚C for 5 minutes in the presence of NADH linked 
substrates (pyruvate 5mM and malate 5mM) with or without (control) AngII (in 
concentrations of 0.1 µM or 1 µM). After 5 minutes, respiratory States were 
measured as described in Methods Chapter 2.8.4. 
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Figure 27. Respiration rates of isolated liver mitochondria in the presence of malate and 
pyruvate. Data are taken from three independent preparations (n=3). There was no significant 
effect of AngII on basal, State 3 or State 4 respiration at either 0.1 µM (A) or 1 µM (B). Data 
represent mean ± SEM and differences between AngII and control groups were assessed using 
paired sample t-tests. 
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 ADP/O  RCR 
Control 3.20 ± 0.19 7.26 ± 0.40 
AngII (0.1 µM) 3.23 ± 0.30 (NS) 7.13 ± 0.28 (NS) 
AngII (1 µM) 3.21 ± 0.46 (NS) 7.58 ± 0.42 (NS) 
 
Table 18. Coupling and efficiency of OXPHOS in mitochondria exposed to AngII. Using State 
4oligo to calculate RCR (RCRoligo), there was no significant effect of AngII on RCR or ADP/O ratio. 
Data represent mean ± SEM. Differences vs. control were assessed using paired sample t-tests. 
NS; non-significant.  
 
These experiments do not provide any evidence for an effect of AngII on 
mitochondrial respiration. The absolute rates of respiration (basal, State 3 and State 
4oligo) were unchanged in the presence of AngII at 0.1 µM and 1 µM. State 3 
respiration reflects the activity of ATP turnover (encompassing adenine nucleotide 
translocase activity, phosphate transportation and ATP synthase) and substrate 
oxidation (involving substrate uptake, TCA enzyme activity, ETS complex activities, 
the available pool of ubiquinone and cytochrome C, and [O2]). An unaltered State 3 
implies that theses aspects of OXPHOS function are not affected by AngII. 
Meanwhile, State 4oligo predominantly reflects proton leak and is therefore a good 
measure of membrane integrity, LEAK, proton slip and uncoupling. A lack of 
difference in State 4oligo respiration rates suggests that AngII does not modulate 
proton leak. These conclusions are supported by the maintained RCR in AngII 
treated mitochondria. 
The ADP/O ratio is often used as a measure of mitochondrial OXPHOS ‘efficiency’ 
(see p.72). Change in ADP/O predominantly reflects alterations in the coupling 
mechanism itself i.e. proton slip (at complexes I, III and IV). The lack of change in 
ADP/O ratios in the presence of AngII therefore suggests no direct effect on 
respiratory complex efficiencies.  
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These data do not, however, entirely rule out an effect of AngII on mitochondrial 
respiration. Whilst the absolute respiratory rates and RCR provide a relatively 
sensitive overview of mitochondrial respiration, they may not identify more subtle 
defects of respiration at individual complexes of the ETS. In reporting respiration 
with malate and pyruvate as substrates, complex II function cannot be commented 
on. Complex II is not involved in respiration on malate/pyruvate in isolated 
mitochondria (Fig. 28). In the presence of high malate concentrations, fumarate 
levels quickly equilibrate, inhibiting succinate reduction at succinate dehydrogenase 
(complex II) and therefore preventing FADH2.formation. Additionally, due to the high 
activity of the tricarboxylate carrier in liver mitochondria, in the presence of high 
malate concentration, citrate is lost to the cytoplasm (or respiration medium) limiting 
forward flux to succinate (Gnaiger 2007). 
Figure 28. Metabolism of pyruvate and malate in insolated liver mitochondria. Pyruvate is 
converted to acetyl-CoA by pyruvate dehydrogenase forming NADH which supplies electrons 
to complex I (1), whilst acetyl-CoA enters the TCA cycle forming citrate from combination with 
oxaloacetate. In the presence of high malate concentrations, citrate is lost to the matrix in 
exchange for malate influx via the tricarboxylate carrier (2) with subsequent decreased 
succinate formation (3). High malate concentrations also equilibrate with fumarate thus 
decreasing forward flux from succinate to fumarate (4). There is also a direct inhibitory effect of 
oxaloacetate (increased in this context) on succinate dehydrogenase (5).  
134 
 
Further, the AngII concentrations applied in these experiments may have been 
suboptimal in timing and dose. A dose dependent effect of AngII in renal proximal 
tubule transport has been described; picomolar AngII concentrations have a 
stimulatory effect and a nanomolar - macromolar concentration causes inhibition 
(Shirai et al. 2014). Therefore, further experiments were conducted using a broader 
range of AngII concentrations, whilst interrogating individual complexes of the ETS.  
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6.4. Effect of AngII on individual complexes of the ETC in isolated 
mitochondria 
To investigate the effect of AngII on individual complexes of the respiratory chain, 
high resolution respirometry was performed with isolated mitochondria. These 
experiments were conducted using the Oxygraph-2K (Oroboros Instruments, 
Innsbruck, Austria). Substrate-uncoupler-inhibitor titration (SUIT) protocols were 
used to isolate individual complexes of the ETS and measure respiration rates in 
State 3 and State 4. RCR was also calculated. Doses of AngII used were extended 
to range from 1 nM to 1000 nM. 
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Figure 29. Respiration rates at complex I with and without (control) AngII. State 3 respiration 
was measured in the presence of malate (5 mM) and glutamate (10 mM) after addition of ADP 
(0.5 mM). Data presented as dots (n=9)  with mean and 95% confidence intervals marked. 
Difference between treatment and control samples was assessed using one-way ANOVA and 
Dunnett’s post hoc test for multiple comparisons. There were no significant effects of AngII at 
1, 10, 100 or 1000 nM concentrations on State 3 or State 4 respiration. There were no significant 
differences in RCR (p < 0.05 considered significant for AngII vs. controls). 
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Figure 30. Respiration rates at complex II with and without (control) AngII. State 3 respiration 
was measured in the presence of rotenone (0.5 µM) and succinate (10 mM) after addition of ADP 
(0.5 mM). Data presented as dots (n=9) with mean and 95% confidence intervals marked. 
Difference between treatment and control samples was assessed using one-way ANOVA and 
Dunnett’s post hoc test for multiple comparisons. There were no significant effects of AngII at 
1, 10, 100 or 1000 nM concentrations on State 3 or State 4 respiration. There were no significant 
differences in RCR (p < 0.05 considered significant for AngII vs. controls). 
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Figure 31. Respiration rates at complex IV with and without (control) AngII. State 3 respiration 
was measured in the presence of ascorbate and TMPD after addition of ADP (0.5mM). Values 
were corrected for auto-oxidation of substrates by addition of sodium azide. Data presented as 
dots (n=9) with mean and 95% confidence intervals marked. Difference between treatment and 
control samples was assessed using one-way ANOVA and Dunnett’s post hoc test for multiple 
comparisons. There were no significant effects of AngII at 1, 10, 100 or 1000 nM concentrations 
on State 3 respiration (p < 0.05 considered significant for AngII vs. controls). 
 
These graphs show that presence of AngII in concentrations ranging from 1 nM to 1 
µM has no significant effect on respiration at complex I, II or IV.  
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6.5. Effect of acute addition of AngII on ETS complex function 
Although no significant effects on mitochondrial respiration were seen in response 
to incubation with AngII, it is conceivable that AngII has a short lasting action on 
mitochondria, occurring within a shorter time frame. This is supported by estimates 
of the half-life of AngII in the circulation as approximating 16 ± 1 seconds (Al-Merani 
et al. 1978). 
To investigate whether there was a short-lived effect of AngII on mitochondrial 
respiration, experiments were conducted in which AngII was added to mitochondria 
respiring on complex I or complex II substrates in the presence of ADP (State 3). A 
difference in respiration rates before and after the addition of AngII was sought. 
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Figure 32. Effect of acute addition of AngII on State 3 respiration at (A) complex I and (B) 
complex II. No significant effect was observed with acute addition of AngII at either 10 nM or 
100 nM at complex I or complex II. Data represent mean ± SEM. Differences were assessed 
using paired sample t-tests. 
As shown in Figure 33, acute addition of AngII at either 10 nM or 100 nM did not 
have any significant effect on State 3 respiration at either complex I or complex II. 
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6.6. Conclusions 
In these experiments, an effect of AngII on mitochondrial respiration was sought by 
measuring oxygen consumption rates of isolated liver mitochondria. Incubation of 
resting mitochondria (in the absence of exogenous substrates or ADP) with 1 µM 
AngII caused no significant change in respiration suggesting that there is no effect 
of AngII on mitochondrial inner membrane integrity or basal proton leak in the 
resting (unstimulated) state. 
An effect of AngII on ‘actively’ respiring mitochondria was then sought. As a primary 
survey of overall mitochondrial respiration, isolated liver mitochondria were 
incubated with NADH linked substrates and respiratory capacity was assessed. 
Following a 5 minute incubation with AngII (100 nM or 1000 nM) or placebo at 37 ˚C, 
no effect on overall respiratory rates could be demonstrated, with RCR and ADP/O 
ratios unaltered. 
Interrogation of individual complexes of the ETS failed to demonstrate any inhibitory 
effect of AngII on mitochondrial respiration at complexes I, II and IV in 
concentrations ranging from 1 nm to 1 µM. This represents [AngII] in physiological 
to supraphysiological levels. The concentration of circulating AngII in rats is in the 
picomolar range, whilst tissue levels range from picomolar to low nanomolar 
concentrations depending on organ (Kai et al. 1998; Liu et al. 2011; Nishiyama et al. 
2003). Though intracellular concentrations have not been defined, the sub-
nanomolar affinity of the AT1R and AT2R in the radioligand binding assays would 
suggest similarly low intracellular concentrations in vivo.  
These data are in contradiction to data reported by Abadir et al who described 
decreased State 3 respiration in isolated liver mitochondria in response to the 
synthetic AT2R agonist CGP421140 (Abadir et al. 2011). However, no effect was 
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detailed with AngII, and so the physiological relevance of such finding must be 
questioned.  
The physiological relevance of these data has also to be questioned in other ways. 
Assessment of mitochondrial function using oxygen consumption of isolated 
mitochondria in a respirometry chamber is a well-established model. However, this 
in vitro setting differs from the in vivo environment on many counts. The O2 tension 
applied in most protocols is higher than in vivo, a necessary measure in order to 
allow for oxygen consumption during experimental protocols. Substrate 
concentrations are supra-physiological, with [succinate] being particularly 
anomalous; the cellular physiological concentration of succinate in healthy cells is 
negligible (Shabalina & Nedergaard 2011). Isolating ETS complex function by 
supplying NADH linked substrates and FADH linked substrates is also 
unphysiological; in vivo, both complex I and complex II are active, with electron flow 
meeting at the Q junction. By assessing maximal respiration without accounting for 
flux through complex II, the protocols used may have underestimated State 3 
respiration. Finally, the concept of respiratory states as defined by Chance and 
Williams are by design not physiological; it is unlikely that mitochondria are ever 
maximally respiring, nor in true State 4 (evidenced by the fact that oligomycin 
applied to most cell preparations will cause a decrease in the respiratory rate). 
A particular disadvantage of working with isolated mitochondria is that they are 
removed from, and can no longer interact with, their cellular environment. This is 
important given the roles mitochondria are now appreciated to play in cell signalling 
pathways. With regards respiration, this results in accumulation of some TCA cycle 
intermediaries whilst others are consumed or lost to the respiratory medium when in 
vivo they would be cycled back from the cytoplasm (Rasmussen et al. 2001). 
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However, accepting these limitations, the lack of effect of AngII (in the physiological 
range) on isolated mitochondrial respiration strongly suggests absence of a 
functioning mitochondrial RAS or any direct effect of intracrine AngII on the 
organelle in rat liver.  
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7. DISCUSSION 
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7.1. Summary of findings 
Given the weight of evidence in the literature supporting an effect of RAS on cellular 
energetics, of an intracellular site of action for AngII and of the pivotal role that 
mitochondria play in regulating cellular bioenergetic state, the possibility of a 
mitochondrial RAS orchestrating aspects of mitochondrial function was an attractive 
hypothesis. However, the data presented in this thesis provide no evidence for such 
a system, in rat liver mitochondria at least.  
Analysing the proteome of the mitochondrial fractions isolated by sequential 
centrifugation of rat liver homogenates did not identify any integral member of the 
RAS family. The presence of neurolysin in the pure mitochondrial fraction warranted 
discussion given its identification as a novel AngII binding protein in rat brain 
homogenates in vitro. However, there is no evidence that neurolysin binds AngII in 
liver, and no evidence for the AngII binding capacity of neurolysin in vivo. 
Given that the pure mitochondrial fraction only contained 27.8% of known 
mitochondrial proteins, a survey of existing mitochondrial proteome databases was 
conducted. None of the recognised first-order RAS proteins were found; in particular 
no AngII receptor was present. Whilst these data made the existence of a liver 
mitochondrial RAS less likely, they could not completely refute the hypothesis since 
proteins expressed in low abundance may not be recognised in a general proteomic 
screen.  
Thus, immunochemistry was employed to identify mitochondrial RAS proteins. 
Accepting that enzymes and effector proteins of the RAS may only be fleetingly 
associated with mitochondria, efforts concentrated on identifying an AngII receptor 
(namely AT1R and AT2R). With immunoreactive bands identified at the appropriate 
weights for both receptors, immunoprecipitation was employed to increase the 
protein yield and, therefore, the sensitivity of mass spectrometry. Mass 
145 
 
spectrometry failed to identify any AngII receptor peptides. However, this work was 
undermined by the non-specific nature of the primary antibodies employed. For the 
same reason, the results of Western blotting using these antibodies have to be 
ignored. 
In the absence of specific antibodies, a pharmacological approach was taken to 
identify possible mitochondrial AngII binding sites. Employing the radioiodinated 
version of the major physiological RAS ligand (125I-AngII), specific binding to a single 
receptor population was demonstrated in both the pure mitochondrial and MAM 
fractions. However, the low abundance of receptors in the pure mitochondria is not 
consistent with a functioning G protein-coupled receptor system, and likely the result 
of contamination with MAM. This is supported by the mass spectrometry data 
showing only 64.9% of the proteins in the pure mitochondrial fraction to be 
mitochondrial. The identity of the AngII binding site in the MAM was confirmed as 
AT1R by competition binding assays.  
Whether MAM AT1Rs represent a functional mitochondrial-associated RAS system 
or whether AngII has a direct non-canonical action at the mitochondrion was 
investigated with respirometry assays. AngII had no effect on respiration in 
concentrations ranging from physiological to supra-physiological concentrations, 
making an in vivo action unlikely. 
These data strongly suggest that a mitochondrial associated RAS does not exist in 
rat liver mitochondria. This is in contradiction to much of the literature cited in 
support of this hypothesis. Reconciling these data requires close inspection of the 
published work. 
7.2. Reconciling these findings with the literature 
Much of the published data in support of a mitochondrial RAS is reliant in part, or 
entirely, on non-specific antibodies and must therefore be treated with caution. In 
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the study by Benicky et al, all the commonly employed AT1R antibodies were shown 
to be non-specific. Given the reliance of Western blotting, immunoprecipitation, 
immunocytochemistry and flow cytometry on antibody specificity, the validity of a 
large body of published work must be questioned. Indeed, up to March 2012, 3,360 
publications were listed on PubMed under the search term ‘Angiotensin II AT1 
receptor antibodies’, whilst 338 results were reported under the term ‘AT1 receptor 
western blotting’ (Benicky et al. 2012). A similar story is apparent with regards AT2R 
antibodies (Hafko et al. 2013).  
With this in mind, re-examination of the data cited in support of my hypothesis leads 
to a less convincing story. Abadir et al argue for the presence of functional AT2R in 
mitochondria from rat heart and liver in direct contradiction with my data. However, 
in the immunogold and immunofluorescence labelling studies they employed a 
Santa Cruz AT2R antibody (Sc-9040) now known to be non-specific. The work by 
Huang et al is often cited as evidence for mitochondrial AT1R (Huang et al. 2003). 
However, the immunolabelling pattern in this study actually showed binding in the 
ER near mitochondria (likely the MAM), but not within mitochondria. There are also 
questions regarding the specificity of the antibody they raised against the carboxyl 
terminal of AT1R.  
Erdmann et al demonstrated immunolabelled AngII within mitochondria of rat 
adrenal, liver and brain tissue (Erdmann et al. 1996). However, evidence of 
specificity for the antibody against AngII was not provided and the authors admit a 
significant proportion of this binding was non-specific. 
In cells of the adrenal cortex and zona glomerulosa, Peters et al demonstrated 
‘dense bodies’ containing renin (with or without angiotensinogen) in the 
mitochondrial fraction on subcellular fractionation (Peters et al. 1996). However, 
using the same technique, Mizuno showed the dense bodies to be distinct from 
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mitochondria (Mizuno et al. 1991). Again, evidence of specificity for the antibodies 
employed is not provided in this or associated work (Wanka et al. 2009; Inagami et 
al. 1980). 
Of the work not relying on specific antibodies, Clausmeyer et al reported a 
mitochondrially targeted renin which could be imported across the membrane 
(Clausmeyer et al. 1999). Whilst the evidence for an alternative renin transcript 
lacking the secretary signal is convincing in cardiac and adrenal tissue at least, 
(Clausmeyer et al. 2000) its import into mitochondria has not been demonstrated. It 
has been shown that a truncated prorenin construct can be imported across the 
mitochondrial membrane but this construct differs in structure from the identified 
cytosolic renin. 
What of the literature involving radioligand binding studies? Van Kats reported [125I]-
AngII  binding in the mitochondrial fraction of both renal and adrenal homogenates 
(van Kats et al. 2001). However, these binding studies were conducted with a crude 
mitochondrial fraction, with evidence in their paper of significant contamination of 
that fraction with lysosomes and microsomes.  
The more convincing evidence is that of mitochondrial [125I]-AngII binding in rat brain 
homogenates (Nancy E. Sirett et al. 1977). Whilst the majority of binding occurred in 
the microsomal fraction, and some of the binding may have been non-specific, it 
does seem that binding occurred in the pure mitochondrial fraction. This suggests 
that [125I]-AngII binding differs in rat liver and brain. Given the in vitro AngII binding 
property of mitochondrial neurolysin differs in brain and liver this perhaps should not 
surprise. Additionally, some caution is necessary when translating these finding to in 
vivo settings; binding was shown only in the presence of EDTA and as such, in a 
non-physiological environment.  
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Finally, the evidence for AngII trafficking to the mitochondria of cardiac muscle 
provided by Robertson et al (Robertson & Khairallah 1971) is limited to a single 
comment in text without any supporting images or data and is therefore difficult to 
evaluate.  
7.3. Do MAM AT1R represent a mitochondrial-associated RAS? 
The AT1R identified in the MAM by radioligand binding studies are in a high enough 
density to be compatible with a functional G-protein linked receptor signalling 
system. It is now widely appreciated that signalling at the MAM-mitochondrial 
interface can influence many aspects of mitochondrial function including respiration 
(see Introduction section 1.9, pp.39-40). However, in respirometry studies 
conducted with crude mitochondria (and therefore including MAM), no 
physiologically relevant functional effect of AngII could be demonstrated. This can 
be explained in two ways. In the first scenario, the AT1R in the MAM are bystanders; 
present only as a consequence of their passing through the ER on the way to or 
from the plasma membrane or nucleus. In support of this, a trafficking pathway for 
plasma membrane AT1R via the Golgi apparatus and ER has been described 
(Hunyady et al. 2002; Bkaily et al. 2003; Cook & Re 2009) whilst it is known that the 
portion of the ER forming the MAM is fluid with both mitochondrial and MAM 
surfaces in constant flux (Grimm 2012).  
In the second scenario, the MAM AT1R do influence mitochondrial function in vivo, 
but this system is rendered dysfunctional by the process of ex vivo isolation. The 
proximity of MAM to the outer mitochondrial membrane (OMM) seems to be vital for 
efficient signalling (Csordás et al. 2006; Csordás & Hajnóczky 2009). Although the 
tethering between OMM and MAM is tight enough to withstand centrifugation at 
10,000 g, the distance between membranes in crude mitochondrial preparations 
may be altered, making the MAM signalling domain dysfunctional. Further, it is 
unclear whether MAM retains the capacity to release Ca2+ in vitro, which appears 
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integral to most MAM signalling processes. Additionally, the respiration medium 
includes the Ca2+ chelating agent EGTA which may limit ER Ca2+ accumulation.  
One way to determine whether isolated crude mitochondria retain functional MAM-
mitochondrial domains would be to measure mitochondrial response to MAM 
receptor stimulation. With the very recent advancements in high resolution 
respirometry allowing measurement of mitochondrial membrane potential and [Ca2+] 
in the chamber (Fasching & Gnaiger 2009), MAM IP3R stimulation using IP3 may 
provide an answer to this question.  
Functional imaging may provide an alternative method for interrogating MAM AT1R 
signalling. Replicating experiments in which AngII is injected intracellularly in cells in 
which plasma membrane receptors have been blocked with losartan may provide a 
model whereby the mitochondrial response (Ca2+ accumulation or membrane 
depolarization) in the presence or absence of candidate MAM signalling cascade 
agonists might be measured. 
7.4. Alternative mechanisms to explain mitochondrial effects of 
AngII 
If a direct action of AngII on mitochondria does not exist, an alternative explanation 
is needed for the documented effects of AngII on mitochondrial physiology. Given 
the plethora of signalling pathways activated by AngII receptor binding there are 
many potential mechanisms. Of these, the role of NAD(P)H oxidases (Nox) seem 
worthy of particular inspection.  
The AngII stimulated increase in mitochondrial ROS, decreased mitochondrial 
membrane potential and decreased RCR are all attenuated by inhibition of Nox 
(Doughan et al. 2008). Evidence also suggests that the stimulation of mitochondrial 
ROS by AT1R requires the full activity of Nox and may depend on the activation of 
mitochondrial KATP channels (Dikalov & Nazarewicz 2013). Activation of plasma 
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membrane Nox by AT1R is well described and Nox have since been shown to be 
expressed in renal nuclei where signalling appears to be via an AT1R-PKC-PI3 
dependent pathway (Seshiah et al. 2002; Pendergrass et al. 2009). Moreover, 
recent work suggests the presence of a Nox subtype (Nox4) in mitochondria of renal 
(Block et al. 2009) and cardiac cells (Kuroda et al. 2010; Ago et al. 2010) where it 
induces H2O2 production and reduces respiratory capacity, possibly by decreased 
complex I activity (Kozieł et al. 2013). Finally, numerous groups have produced 
work suggesting AngII induces increased Nox4 expression in mitochondria of 
various tissues (Lee et al. 2013; Kim et al. 2012; Horne et al. 2012; Case et al. 
2013). Taken together these data suggest AngII may be operating through Nox4 to 
influence mitochondrial physiology.  
However, although these data are intriguing, they are not conclusive. Other groups 
have failed to demonstrate mitochondrial Nox1, Nox2 or Nox4 (Doughan et al. 2008) 
whilst the specificities of the antibodies commonly employed have been questioned 
(Dikalov & Nazarewicz 2013). The concentration of AngII used in most studies is 
supra-physiological (1 µM) and no study has been able to demonstrate Nox4 activity 
in mitochondrial preparations. Furthermore, mitochondrial ROS production can be 
independent of Nox whilst the contribution of mito KATP to membrane potential is 
only approximately 1-2 mV implying that the changes in potential seen with AngII 
are more likely due to other mechanisms. 
One such mechanism might depend on the activity of uncoupling proteins; the 
stimulation of mitochondrial ROS by AngII may be due to a decrease in the ability to 
uncouple OXPHOS. In support of this hypothesis, renal mitochondria of 
spontaneously hypertensive rats show increased UCP2 expression following AT1R 
blockade whilst in an aging rat model both ACE inhibition and AT1R blockade were 
associated with higher UCP2 concentrations in renal mitochondria (de Cavanagh et 
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al. 2003). The influence of AngII and other RAS components on UCP2 expression 
warrants further investigation.  
7.5. Conclusion 
My hypothesis stated that a mitochondrial RAS exists in liver mitochondria. These 
data do not support this hypothesis, and whilst it is difficult to conclusively prove the 
absence of a RAS, the weight of evidence is strongly against its existence. I cannot, 
however, exclude the presence of a mitochondrial RAS in other tissues, since 
mitochondrial biochemistry is heterogeneous between organs, and even within 
tissues. Further work in other organs is required to investigate this possibility. The 
mechanism(s) by which AngII influences mitochondrial physiology is still unclear 
and studies should concentrate on investigating other pathways, with Nox and UCP 
modulation foremost among them.  
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1.1. Isolation of mitochondria and other subcellular fractions 
Reagents 
AngII (1 µM stock)  # 151039 M005, Alexis biochemicals, Exeter, UK 
Ethylenediaminetetraacetic acid (EDTA): 100 mM 
Phenylmethanesulfonyl fluoride (PMSF), 100nM 
Protease inhibitor cocktail:  Complete Mini, EDTA free, Roche, Herts, UK 
Proteinase K:   P6556, Sigma-Aldrich, MO, USA 
Sodium carbonate,   100mM (pH 11.5) 
TCA 72% 
 
Solutions 
Isolation medium A  
Ion/Reagent Molecular Weight Final Concentration 
Mannitol 182.17 250 mM 
EGTA 380.4 0.5 mM 
4-(2-hydroxyethyl)-1-
piperazineethanesulfonic 
acid (HEPES 
283.3 5 mM, pH 7.4 
Isolation medium B 
Ion/Reagent Molecular Weight Final Concentration 
Mannitol 182.17 225 mM 
EGTA 380.4 5 mM 
HEPES 283.3 25 mM, pH 7.4 
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1.2. Protein quantification 
Materials 
Protease inhibitor cocktail  Complete Mini, EDTA free, Roche, Herts, UK 
Phosphatase inhibitors  PhosStop, Roche, Herts, UK 
BCA protein assay reagent kit Pierce, Rockford, IL, USA 
 
Solutions 
Lysis buffer 
Ion/Reagent Molecular Weight Final 
Concentration 
Tris (pH 6.8) 121.3 100 mM, pH 6.8 
NaCl 58 300 mM 
nonyl 
phenoxypolyethoxylethanol -
40 (NP-40) 
617 0.5% 
H2O 18 70% 
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1.3. Western blotting 
Materials 
Coomassie Brilliant Blue: R-250, Life Sciences, UK. 
Primary antibodies 
As listed in results section 
Secondary antibodies 
Antibody Company Concentration 
Rabbit Anti-Goat IgG  
HRP conjugate 
 
Invitrogen 
(Carlsbad, CA, 
USA) 
1:4000 
Donkey Anti-mouse IgG  
HRP conjugate 
 
Invitrogen 
(Carlsbad, CA, 
USA) 
1:4000 
Goat Anti-rabbit IgG 
HRP conjugate 
 
Invitrogen 
(Carlsbad, CA, 
USA) 
1:4000 
 
Solutions 
Laemmli buffer 
Ion/Reagent Molecular Weight 
(g mol-1) 
Final 
Concentration 
Tris (pH 6.8) in  
80% water/20% glycerol 
121.3 0.125 M 
Sodium dodecyl sulphate 
(SDS) 
288.4 4% 
2-mercaptoethanol - 10% 
Bromophenol blue - 0.004% 
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Running buffer 
20 x MOPS (diluted x20 with H2O before use) 
Ion/Reagent Molecular Weight 
(g mol-1) 
Final Concentration 
MOPS 209.3 1 M 
Tris 121.1 1 M 
SDS 288.4 2 % 
EDTA 292.3 10 mM 
 
Transfer buffer 
Ion/Reagent Molecular Weight 
(g mol-1) 
Final Concentration 
Bicine 163.2 25 mM 
Bis Tris 209.3 25 mM 
EDTA 292.3 1 mM 
 
Phosphate buffered saline Tween 20 (PBST) 
Ion/Reagent Final Concentration 
Tween 20  0.5% (diluted in PBS) 
 
Coomassie Brilliant Blue stain 
Ion/Reagent Final Concentration 
Acetic acid 7% 
Ethanol 40% 
Coomassie Brillaint 
Blue 
0.1% 
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1.4. Radioligand binding studies 
Materials 
Losartan   # 3798, Torcis Bioscience, Bristol, UK 
PD123319   # 1361, Torcis Bioscience, Bristol, UK 
[125I]Tyr4-AngII (2200 Ci/mmol, 81.4 TBq/mmol): PerkinElmer, Cambridge, UK 
 
Solutions 
Radioligand assay buffer 
Ion/Reagent Molecular Weight  
(g mol-1) 
Final Concentration 
NaH2PO4 268 50 mM (pH 7.4) 
NaCl 58 100 mM 
EGTA 380.4 1 mM 
MgCl2 95.2 10 mM 
BSA 66.5 0.2% (pH 7.4) 
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1.5. Respirometry 
Materials 
Antimycin A  A8574, Sigma Aldrich, MO, USA 
AngII (1 µM stock)  # 151039 M005, Alexis biochemicals, Exeter, UK 
Ascorbate  A4034, Sigma Aldrich, MO, USA 
Glutamate  G1626, Sigma Aldrich, MO, USA 
Losartan   # 3798, Torcis Bioscience, Bristol, UK 
Malate   M9546, Sigma Aldrich, MO, USA 
Oligomycin   75351, Sigma-Aldrich, MO, USA 
PD123319   # 3798, Torcis Bioscience, Bristol, UK 
Pyruvate  P8547, Sigma Aldrich, MO, USA 
Rotenone  R8875, Sigma-Aldrich, MO, USA 
Sodium Azide  S2002 Sigma-Aldrich, MO, USA 
Succinate  S3674, Sigma-Aldrich, MO, USA 
TMPD   T3134, Sigma-Aldrich, MO, USA 
Solutions 
Respiration medium 
Ion/Reagent Molecular Weight 
(g mol-1) 
Final Concentration 
Sucrose 342.3 110 mM 
 MgCl2 95.2 3.0 mM 
EGTA 380.4 0.5 mM 
KCl 74.55 80 mM 
K-lactobionate 358.3 60 mM 
KH2PO4, 136 10 mM 
Taurine 125.2 20 mM 
HEPES 238.3 20 mM 
BSA 66.5 1.0 gL-1 , pH 7.1 
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Generation of RAS search terms 
Gene ontology (GO) terms relating to the RAS were found using the AmiGO 
database (http://amigo.geneontology.org/amigo). The corresponding gene product 
names were identified using UniProt (http://uniprot.org/). The list detailed below was 
then compared to exiting mitochondrial databases (MitoCarta, MitoMiner) or reports 
of proteins identified by mass spectrometry of the PM, CM or MAM.  
Entry Entry name Protein names Gene names 
Q5EGZ1 ACE2_RAT Angiotensin-converting enzyme 2(ACE-related 
carboxypeptidase)  
Ace2 
P47820 ACE_RAT Angiotensin-converting enzyme (ACE) [Cleaved 
into: Angiotensin-converting enzyme, soluble 
form] 
Ace Dcp1 
P35351 AGTR2_RAT Type-2 angiotensin II receptor (Angiotensin II 
type-2 receptor) (AT2) 
Agtr2 
P25095 AGTRA_RAT Type-1A angiotensin II receptor (Angiotensin II 
type-1A receptor) (AT1A) 
Agtr1 Agtr1a 
At1a 
P29089 AGTRB_RAT Type-1B angiotensin II receptor (AT3) (Angiotensin 
II type-1B receptor) (AT1B) 
Agtr1b Agtr1 
At1b 
O09175 AMPB_RAT Aminopeptidase B (Arginine 
aminopeptidase)(Cytosol aminopeptidase IV) 
Rnpep 
P50123 AMPE_RAT Glutamyl aminopeptidase (Aminopeptidase A) 
(AP-A) (CD antigen CD249) 
Enpep 
P15684 AMPN_RAT Aminopeptidase N (AP-N) (Alanyl aminopeptidase) 
(Aminopeptidase M) (AP-M) (Kidney Zn peptidase) 
(KZP) (Microsomal aminopeptidase)  
Anpep 
P01015 ANGT_RAT Angiotensinogen (Serpin A8) [Cleaved into: 
Angiotensin-1 (Angiotensin 1-10) (Angiotensin I) 
(Ang I); Angiotensin-2 (Angiotensin 1-8) 
(Angiotensin II) (Ang II); Angiotensin-3 
(Angiotensin 2-8) (Angiotensin III) (Ang III) (Des-
Asp[1]-angiotensin II); Angiotensin-4 (Angiotensin 
3-8) (Angiotensin IV) (Ang IV); Angiotensin 1-9; 
Angiotensin 1-7; Angiotensin 1-5; Angiotensin 1-4] 
Agt Serpina8 
P29066 ARRB1_RAT Beta-arrestin-1 (Arrestin beta-1) Arrb1 
P29067 ARRB2_RAT Beta-arrestin-2 (Arrestin beta-2) Arrb2 
Q642A2 ATRAP_RAT Type-1 angiotensin II receptor-associated protein 
(AT1 receptor-associated protein) 
Agtrap Atrap 
P25023 BKRB2_RAT B2 bradykinin receptor (B2R) (BK-2 receptor) Bdkrb2 
P30099 C11B2_RAT Cytochrome P450 11B2, mitochondrial 
(Aldosterone synthase) (CYPXIB2) (Cytochrome 
P450-Aldo-1 
Cyp11b2 
Cyp11b-2 
P30100 C11B3_RAT Cytochrome P450 11B3, mitochondrial 
(Aldosterone synthase) (CYPXIB3) (Cytochrome 
P450-Aldo-2 
Cyp11b3 
Cyp11b-3 
P00787 CATB_RAT Cathepsin B (EC 3.4.22.1) (Cathepsin B1 [Cleaved 
into: Cathepsin B light chain; Cathepsin B heavy 
chain] 
Ctsb 
P16228 CATE_RAT Cathepsin E (EC 3.4.23.34) Ctse 
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P00786 CATH_RAT Pro-cathepsin H [Cleaved into: Cathepsin H mini 
chain; Cathepsin H Cathepsin H heavy chain; 
Cathepsin H light chain] 
Ctsh 
P21961 CBPA3_RAT Mast cell carboxypeptidase A (EC 3.4.17.1) 
(Carboxypeptidase A3)  
Cpa3 
P28234 CXA5_RAT Gap junction alpha-5 protein (Connexin-40) (Cx40) Gja5 Cxn-40 
Q62737 CY24A_RAT Cytochrome b-245 light chain (Cytochrome b(558) 
alpha chain) (Cytochrome b558 subunit alpha) 
(Neutrophil cytochrome b 22 kDa polypeptide) 
(Superoxide-generating NADPH oxidase light chain 
subunit)  
Cyba 
P19020 DRD3_RAT D(3) dopamine receptor (Dopamine D3 receptor) Drd3 
P42893 ECE1_RAT Endothelin-converting enzyme 1  Ece1 
Q99372 ELN_RAT Elastin (Tropoelastin) Eln 
P05370 G6PD_RAT Glucose-6-phosphate 1-dehydrogenase (G6PD)  G6pdx G6pd 
P54311 GBB1_RAT Guanine nucleotide-binding protein G(I)/G(S)/G(T) 
subunit beta-1 (Transducin beta chain 1) 
Gnb1 
P54313 GBB2_RAT Guanine nucleotide-binding protein G(I)/G(S)/G(T) 
subunit beta-2 (G protein subunit beta-2) 
(Transducin beta chain 2) 
Gnb2 
O35353 GBB4_RAT Guanine nucleotide-binding protein subunit beta-
4 (Transducin beta chain 4) 
Gnb4 
Q62689 JAK2_RAT Tyrosine-protein kinase JAK2 (EC 2.7.10.2) (Janus 
kinase 2) (JAK-2) 
Jak2 
P00759 KLK2_RAT Tonin (EC 3.4.21.35) (Esterase 1) (Glandular 
kallikrein-2)  
Klk2 Klk-2 Ton 
P97629 LCAP_RAT Leucyl-cystinyl aminopeptidase (Cystinyl 
aminopeptidase) (EC 3.4.11.3) (GP160) (Insulin-
regulated membrane aminopeptidase) (Insulin-
responsive aminopeptidase)  
Lnpep Irap 
Otase 
Q9R0Q2 LT4R1_RAT Leukotriene B4 receptor 1 (LTB4-R 1) Ltb4r Blt 
P12526 MAS_RAT Proto-oncogene Mas Mas1 Mas Mas-
1 
P09650 MCPT1_RAT Mast cell protease 1 (rMCP-1) (EC 3.4.21.39) 
(Chymase)) 
Mcpt1 
P97592 MCPT4_RAT Mast cell protease 4 (rMCP-4) (EC 3.4.21.-) (Mast 
cell protease IV)  
Mcpt4 
P30904 MIF_RAT Macrophage migration inhibitory factor (MIF) (EC 
5.3.2.1) (Glutathione-binding 13 kDa protein) (L-
dopachrome isomerase) 
Mif 
P07861 NEP_RAT Neprilysin (EC 3.4.24.11) (Atriopeptidase) 
(Enkephalinase) (Neutral endopeptidase 24.11) 
(NEP 
Mme 
P42676 NEUL_RAT Neurolysin, mitochondrial (Microsomal 
endopeptidase) (MEP) (Mitochondrial 
oligopeptidase M) 
Nln 
P14600 NK1R_RAT Substance-P receptor (SPR) (NK-1 receptor) (NK-
1R) (Tachykinin receptor 1) 
Tacr1 Tac1r 
P23441 NKX21_RAT Homeobox protein Nkx-2.1 (Thyroid nuclear factor 
1) (Thyroid transcription factor 1) (TTF-1) 
Nkx2-1 Nkx-2.1 
Titf1 Ttf-1 Ttf1 
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P26824 PAR1_RAT Proteinase-activated receptor 1 (PAR-1) 
(Thrombin receptor) 
F2r Par1 
Q63645 PAR2_RAT Proteinase-activated receptor 2 (PAR-2) 
(Coagulation factor II receptor-like 1) (Thrombin 
receptor-like 1) 
F2rl1 Par2 
P41413 PCSK5_RAT Proprotein convertase subtilisin/kexin type 5 
(Proprotein convertase 5) (PC5) (Proprotein 
convertase 6) (PC6)) 
Pcsk5 
O70196 PPCE_RAT Prolyl endopeptidase (PE) (EC 3.4.21.26) (Post-
proline cleaving enzyme) (rPop) 
Prep 
P08424 RENI_RAT Renin (Angiotensinogenase) Ren1 Ren 
Q6AXS4 RENR_RAT Renin receptor (ATPase H(+)-transporting 
lysosomal accessory protein 2) (ATPase H(+)-
transporting lysosomal-interacting protein 2) 
(Renin/prorenin receptor) 
Atp6ap2 
Atp6ip2 
F1M7S4 F1M7S4_RAT Carboxypeptidase A3 (Mast cell carboxypeptidase 
A) 
Cpa3 
rCG_41643 
Q68FT8 Q68FT8_RAT Protein Serpinf2 (RCG33981, isoform CRA_a) 
(Serine (Or cysteine) peptidase inhibitor, clade F, 
member 2) 
Serpinf2 
rCG_33981 
D3ZD62 D3ZD62_RAT Protein Ndst2 (RCG41904, isoform CRA_c) Ndst2 
rCG_41904 
B1WBL8 B1WBL8_RAT Angiotensin II receptor, type 2 (Angiotensin II 
receptor, type 2, isoform CRA_a) 
Agtr2 
rCG_53260 
D4A7G6 D4A7G6_RAT Protein Gpr25 (RCG45981) Gpr25 
rCG_45981 
C7ECU5 C7ECU5_RAT Angiotensin I converting enzyme 2  Ace2 
rCG_49658 
Q91XT0 Q91XT0_RAT E1A-binding protein (Protein Ep300) Ep300 p300 
D3ZYK4 D3ZYK4_RAT Angiotensin-converting enzyme 2 (Fragment) Ace2 
Q9QX17 Q9QX17_RAT Aminopeptidase N (Fragment) Anpep APN 
D3ZPX6 D3ZPX6_RAT Elastin Eln 
D4AA31 D4AA31_RAT Protein Prcp Prcp 
F1LPS4 F1LPS4_RAT Cytochrome P450 11B2, mitochondrial Cyp11b2 
Q9R258 Q9R258_RAT Renin b (Fragment) Ren Ren1 
Q6BDA5 Q6BDA5_RAT Dual endothelin 1, angiotensin II receptor Dear 
D4A9U4 D4A9U4_RAT Elastin Eln 
Q9JIE2 Q9JIE2_RAT Renin (Fragment) Ren Ren1 
Q9QX18 Q9QX18_RAT Aminopeptidase N (Fragment) Anpep APN 
Table 19. RAS related gene ontology terms. The associated protein names were found using 
the UniProt database.  
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Measuring AngII induced cytosolic Ca2+ flux 
In order to verify the chemical reactivity of the AngII stock solution used for 
respirometry experiments, dynamic measurements of intracellular Ca2+ ([Ca2+]i) 
were made using the cell permeant green-fluorescent Ca2+ indicator Fluo-4 AM.  
HepG2 cells were cultured in RPMI 1640 with Glutamax (Life Technologies, 
Carlbad, Ca, USA) supplemented with 5% heat inactivated fetal calf serum (FCS, 
Biological Industries, Beir Haemak, Isreal) and antibiotics (Penicillin-Streptomycin 
(50 U/mL)). For [Ca2+]I measurements, cells were loaded with 4 µM Fluo-4 AM for 30 
minutes at 37 ˚C in Krebs-Ringer modified buffer containing 1 mM CaCl2 (125 mM 
NaCl, 5 mM KCl, 1 mM MgSO4, 1 mM K2HPO4, 1 mM CaCl2, 5.5 mM glucose, and 
20 mM HEPES [pH 7.4]). 
Loaded cells were imaged with an Olympus IX71 microscope with a 40x lens, and 
images were captured using a Sensicam QE cooled digital CCD camera (Cooke, 
Romulus, MI) at 2.6 seconds intervals. An excitation wavelength of 488 nM was 
used and emitted fluorescence collected above 505 nm. Cells were maintained at 
37 ˚C. 
The Fluo-4 signal was measured before and after addition of 1 µM AngII (# 151039 
M005, Alexis biochemicals, Exeter, UK). The mitochondrial ETS uncoupler p-
Trifluoromethoxy-phenylhydrazone (FCCP), which releases mitochondrial Ca2+ into 
the cytosol was used as a control condition.  
Images were analysed using Metamorph data acquisition software (Visitron 
Systems, West Chester, PA, USA). Ten regions of interest (ROI) were selected (10 
cells) and the Fluo-4 AM fluorescence intensity was measured.  
As shown in Fig 34, 1 µM AngII caused a peak in [Ca2+]I confirming that the 
chemical was stable and reactive at 37 C. 
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Figure 33. Cytosolic Ca
2+
 [Ca
2+
]i measurements in HepG2 cells stimulated by 1 µM AngII. HepG2 
cells were loaded with 4 µM Fluo-4 for 30 minutes. Cells were excited at 488 nM wavelength 
light and imaged using a confocal microscope. Images were acquired during stimulation with 
both 1 µM AngII and 1 µM FCCP. Regions of interest (ROI) were selected and signal intensity 
measured. The increase in intensity following AngII addition indicates [Ca
2+
]I release and 
therefore chemically reactive AngII. 
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